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INTRODUCTION 
 Organophosphorus (OP) compounds are insecticides and are the most common 
cause of poisoning in India.(1) These compounds inhibit the acetylcholinesterase 
(AChE) enzyme which is found in the nerve synapses leading to the accumulation of 
acetylcholine. It can lead to muscarinic symptoms and respiratory failure.(2) The 
mainstays of therapy remain anticholinergic agent, atropine along with general 
supportive measures.(3) Oximes are compounds which can react with the OP inhibited 
enzyme and reactivate the enzyme.(4,5) Oximes, including pralidoxime and 
obidoxime, have shown benefit in several in-vitro studies but evidence in clinical 
settings has been conflicting. Although systematic reviews have not shown significant 
benefit from oxime therapy, recent trials suggest that there may be certain sub-groups 
of patients in whom these agents may be useful.(4,6) It may be possible to identify 
this sub-group by means of the triple cholinesterase test.(7,8) This test requires the 
measurement of the baseline erythrocyte AChE followed by the measurement of the 
same after addition of obidoxime to the blood sample which provides for a measure of 
the reactivability of the enzyme. The assay also assesses the inhibitory effect of the 
patient‘s plasma on control AChE. We attempt to define the characteristics of the 
patient sub-group which are associated with significant enzyme reactivation in whom 
oxime therapy may be effective. 
 The poison database is an important component of the study of the 
epidemiology of poisoning at a regional level. Analysing this database would provide 
valuable information regarding the major poisoning risks in the community and help 
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in improving management of common poisonings.(9,10) This study was designed to 
describe the changing profile of adult poisonings presenting to Christian Medical 
College (CMC), Vellore. We attempted to describe the relative proportions of 
different groups of poisons including pesticides, plants and drugs along with their 
outcomes and their temporal profile. 
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AIM 
To study the role of triple cholinesterase test in the management of Organophosphorus 
(OP) poisoning and the changing trends in the profile of poisoning presenting to a 
tertiary care centre in South India.  
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OBJECTIVES 
 (A) TO EVALUATE TRIPLE CHOLINESTERASE TEST IN 
ORGANOPHOSPHORUS POISONING 
1. To validate a battery of the following tests for use in patients with 
organophosphorus poisoning to determine applicability of oxime therapy – RBC 
acetylcholinesterase(AChE), Plasma butyrylcholinesterase(BChE), enzyme 
reactivating potential of obidoxime ex-vivo and Inhibitory activity of patient 
plasma – and to determine their temporal profile 
2. To correlate these test results to the clinical characteristics of acute 
organophosphate poisoning including type of organophosphate, time to 
presentation, severity of poisoning and development of complications 
3. To determine the clinical characteristics of patients with organophosphorus poisoning in 
whom oxime therapy would be useful. 
(B) TO STUDY THE CHANGING PROFILE OF POISONINGS IN CMC, 
VELLORE BETWEEN 2009-2014 USING THE POISON DATABASE 
1. To study the changing profile of pesticide, plant poisoning and drug overdose 
during the period 2009-2014. 
2. To study the changing demographics of patients who present with poisoning and 
comparison of accidental poisoning and deliberate self-harm due to pesticide, 
plant poisoning and drug over dose. 
3. To study the overall mortality and poison specific mortality in relation to 
pesticide, plant poisoning and drug overdose. 
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A REVIEW OF LITERATURE 
EPIDEMIOLOGY OF POISONING 
The WHO estimates 800,000 deaths due to suicides each year with many more 
attempted suicides. Suicide accounted for 1.4% of deaths in 2012 with over three-
fourths of the cases occurring in the low and middle-income countries.(11) Globally, it 
was also the second most common cause of death in women between 15 to 29 years of 
age. India‘s suicide rate falls in the bracket of >15 per 100,000 population and falls in 
the category of countries with high suicide mortality as shown in the representative 
map below.(11) In 2012, a WHO appraisal estimated that 2.6% of deaths in India 
could be attributed to deliberate self-harm and this rate was on a rising trend.(12)  
 
Figure 1: Age standardized suicide rate (per 100,000 population), 2012 (11) 
  As per the 2011 census in India, “Injury, Poisoning & Certain Other 
Consequences of External Causes” accounted for 7.8% of all medically certified 
deaths and were the leading cause of mortality in the age group of 15-24 and 25-34 
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years accounting for 27.5%  and 23.5% respectively in these groups.(13) This 
signifies the vulnerability of the adolescent age-group and youth to deaths due to 
deliberate self-harm. Poisoning due to drugs, biological substances and non-medicinal 
substances caused 1.5% of all deaths in India in 2010. 71.9% of these deaths occurred 
in the working age-group of 15 to 54 years of age. Data on poisoning has been widely 
fluctuating over the years and between different regions depending on the availability 
of different poisons and the efficacy of reporting systems. The above numbers may be 
an under-estimation as mortality statistics in India are limited by poor reporting 
systems and an evaluation in the census showed that of the total registered deaths in 
the country, only 20% were medically certified.(13) The Million death Study found 
that a 15 year old in India had a cumulative risk of 1.2% of dying by suicide before 80 
years of age with Tamil Nadu being in the highest risk bracket of >2% risk 
(2.2%).(1,14)  
EPIDEMIOLOGY OF PESTICIDE POISONING IN THE WORLD 
Pesticides, although an important component of agricultural practice as a 
defence against pests, are highly toxic and poisoning with these agents is a major 
problem in the developing world, especially in the rural regions. There are an 
estimated 3 million cases of pesticide poisoning worldwide every year resulting in 
250,000 deaths and leaving thousands more in morbidity and disability.(15) Of these 
cases, one-third are accidental and two-thirds are due to deliberate self-harm.(16)  
Most of these cases occurred in India, China, Vietnam and Sri Lanka.(15) 20.7% of 
suicides occurring in south-east Asia are due to pesticides compared to 3.9% and 4.7% 
respectively in Americas and Europe.(17)  
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Figure 2: Pesticides as a cause of fatal self-harm in Asia(15) 
PESTICIDE POISONING – INDIAN SCENARIO 
Poisoning, mainly with OP compounds, account for about half the suicides in 
the country which was estimated as 187,000 deaths every year in the million death 
study.(1) A study done in the state of Maharashtra over a period of five years 
quantitated organophosphorus as the causative agent in 43% of fatalities due to 
poisoning.(18)  What makes pesticide poisoning a popular method for suicide is the 
easy availability of these compounds especially in countries with an agrarian economy 
where these toxic compounds can be bought ―over the counter‖ and lack of knowledge 
about their adverse effects.(19,20) Some studies have also shown that chronic as well 
as acute exposure to organophosphorus can induce affective disorders which may in 
turn increase the suicidal intentions.(21) This led to the recommendation from several 
authors to increase regulations and restrict access to pesticides especially 
organophosphates as part of suicide prevention strategies.(1,16,17,22)  
EFFECT OF RESTRICTIONS ON TOXIC PESTICIDES 
One major contributor to the changes in suicide mortality in high-income 
countries is the change in the lethality and in the availability of the suicide methods 
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commonly used.(23) A study in Sri Lanka showed that after the restriction of toxic 
pesticides, there was a fall in the mortality rates due to poisoning without impacting 
the rate of deliberate self-harm.(24) In Sri Lanka, the most toxic organophosphates, 
namely parathion, methylparathion, monocrotophos and methamidophos were banned 
by 1984 and all WHO class I toxic compounds were banned by 1995. There was a 
transient rise in suicide mortality in the transitional period up to 1995 as endosulfan 
use increased after which endosulfan was also banned in 1998. There was a 
progressive drop in suicide rates thereafter with rates becoming almost halved in 2005 
compared to 1995 indicating that the restriction of toxic pesticides may have limited 
the mortality.   
It is known that having access to easily available and highly toxic pesticides 
increases the rate of deaths due to intentional poisoning. This was proved when the 
change to benzodiazepines from barbiturates led to a fall in mortality due to 
pharmaceutical poisonings.(25) The WHO and FAO recommended progressive ban on 
the class Ia and Ib (extremely and highly hazardous) pesticides and to use alternatives 
for pest management.(26,27) As per these recommendations, several pesticides have 
been restricted or banned from use in India. For example, Monocrotophos is banned 
from use in vegetable crops. Some of the changes suggested to reduce access to toxic 
pesticides include restricting pesticide use to only less toxic compounds and 
subsidizing the costs of these alternative pesticides. Education of farming 
communities and better poisoning management practices have also shown to be 
effective in lowering the poisoning mortality.(28) Eddleston et al propounded the 
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development of a ―minimum pesticides list‖ including  permissible pesticides which 
are less dangerous.(25) 
However, there is no system in place in India to implement the regulations on 
pesticide use.(29) Newer and less toxic pesticides are being progressively introduced 
into the market in India. We know that pesticide restriction has not been effective in 
India. These changes of introduction of newer pesticides and lack of restriction may 
ultimately impact both the profile of poisonings and deaths due to them in the country. 
POISONING IN CMC, VELLORE – A SHIFT IN PROFILE? 
 A surveillance study was done between July 2009 to June 2011 in CMC using 
the poison database.(30) It included 1164 patients with poisoning of whom 52.7% 
were men with 29.4 years being the mean age. 97% of them were due to deliberate 
self-harm with pesticides accounting for 53.4% of which organophosphates were 
implicated in 54% of the cases. Drugs accounted for 28.3% and plant poisons for 
9.5% of all the poisoning cases. During this period, 70% of all the organophosphates 
belonged to the highly toxic class I category with a case fatality rate of 8.4%. 
Organophosphates were also the most common cause of death due to poisoning 
causing 29.1% of all the poisoning deaths. Considering the high mortality rates and 
the high prevalence of the highly toxic group of pesticides, it called for the regulation 
of these pesticides as has been done in several other countries. It also established the 
use of poison data base from the CMC Poison centre in monitoring trends in poisons. 
A study was initiated in CMC, Vellore to examine the pathophysiology of 
shock in the Oduvanthalai poisoning. (Pathophysiological mechanism of 
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cardiovascular toxicity in Oduvanthalai or Cleistanthus collinus poisoning. IRB Min. 
No 8944 dated 7.07.2014) Oduvanthalai poisoning is the most common plant poison 
in Vellore district with a mortality of about 30%.(31)  This study was started in view 
of the lethality and lack of knowledge regarding the pathophysiology and the absence 
of an effective treatment. There was found to be a sharp decline of Oduvanthalai 
poisoning which may reflect a changing epidemiological profile. Oduvanthalai 
poisoning is a traditional method of deliberate self-harm, almost exclusively among 
rural community, more common among women and older people. Although the 
planned study was not possible, the decline in cases of Oduvan poisoning may reflect 
preference of other poisons such as pesticides and drugs among younger people or a 
change in referral pattern. There has also been a perceptible shift in the type of 
pesticides consumed with greater prevalence of less toxic pesticides and mixed 
pesticides. Whether this has impacted the mortality due to poisonings has to be 
evaluated through this study of the poison database.  
POISON INFORMATION CENTRES & TOXICOVIGILANCE 
Many studies have also noted the gross under-reporting of pesticide poisoning 
in India with one study estimating seven times higher mortality than the reported 
rates.(17) This indicates the utility of maintaining a poison database in every hospital 
to determine the exact magnitude of the problem.(29) This led to the WHO advocating 
the establishment of poison centres that specialize in prevention, diagnosis and 
management of poisoning. (32) They also maintain databases that provide data about 
the type of agents used for poisoning, the means by which they were obtained and the 
effects of the poison which could direct further preventive measures. They help in 
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identifying and evaluating existing and emerging toxic hazards in the community 
which is now known as toxicovigilance.(10,32) Toxicovigilance entails detailing the 
toxic risks in the community along with reporting to the appropriate health authorities 
and developing measures to reduce the emerging exposure risks.(9,33) The first such 
poison information centre in the country  was established in the department of 
Pharmacology in All India Institute of Medical Sciences, New Delhi in 1995 and its 
functions include advice on management of poisoning, toxicovigilance, training 
measures for medical personnel and prevention of poisoning.(34) This could guide 
policy-makers in public health settings especially in decisions regarding regulation of 
pesticide use and also in the development of a comprehensive poisoning prevention 
and management programme.(35) In our local region, Poison control centres have 
been established in Madras medical College and Amrita Academy of Medical 
Sciences. 
Medicine Unit I has adopted the function of a poison control centre with 
functions including clinical services, training, documentation, research, community 
outreach and advocacy. It has been prospectively collecting a poisoning data base 
from 2009. We will use this data base to examine the changing hospital based 
epidemiology of poisonings at Christian Medical College. The goals of this data base, 
conforming to the WHO recommendations, are as follows:  
1. To monitor the profile of poisonings and mortality 
2. To audit the care of poisoning patients and provide feedback to clinicians 
3. Provide the basis for guidelines and improvement in clinical care 
4. For public health policy advocacy in preventing poisons. 
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The main role of our CMC, Vellore Poison Control Centre is to collect, collate and 
analyse information about poisoning in the community on a regional basis. It is 
important to determine the magnitude, pattern and outcomes of common poisonings in 
the region. Analysis of this database may reflect the changing profile of poisoning in 
the community and guide preventive measures and also in the early diagnosis and 
management of these common poisonings. 
 
ORGANOPHOSPHORUS COMPOUNDS 
Organophosphorus compounds are popular options for suicide attempts due to 
their easy availability in many Indian households in view of their utility as pesticides. 
Several studies in India have implicated these compounds as the most common cause 
of deliberate self-harm in the country especially among the farming community.(36) 
STRUCTURE OF ORGANOPHOSPHORUS COMPOUNDS  
The pathogenesis of the toxicity of organophosphorus compounds in humans 
was first recognised in the 1930s in Germany. Its structure consists of a tetra-
substituted phosphorous centre with a double bonded oxygen or sulphur atom and a 
leaving group with two other substituents depending on the compound subclass.(37) 
 
Figure 3: Chemical structure of organophosphorus molecule (38) 
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CLASSIFICATION OF ORGANOPHOSPHORUS COMPOUNDS 
The organophosphorus compounds can be classified in various ways as follows(2): 
1. Depending on whether they are pro-poison or active poison 
a) Thion (pro-poison) – Parathion, Chlorpyrifos, Dimethoate – with sulphur atom 
attached to phosphate atom (P=S) and need conversion by CYP450 in gut wall or 
liver to active oxon (P=O) for clinical effects 
b) Active oxon form – Profenofos, Dichlorvos – faster acting as they do not require 
activation 
2. WHO classification based on rat LD50(26)  
 Class Ia (extremely hazardous) – Parathion, Methyl-parathion 
 Class Ib (highly hazardous) – Dichlorvos, Dicrotofos, Monocrotofos, Triazophos 
 Class II (moderately hazardous) – Chlorpyrifos, Diazinon, Fenthion, Quinalphos 
 Class III (slightly hazardous) – Methylchlorpyrifos, Malathion  
- This classification is based on rat toxicity and was applied for occupational use and not 
for deliberate self-harm. Therefore, although class II compounds may be less toxic than 
their class I counterparts, in the setting of self-poisoning, these are highly lethal 
compounds.  
3. Chemical structure (depending on the structure of R1 and R2 – as in chemical 
structure of organophosphorus molecule – Figure 1(38)) 
a. Diethyl – Chlorpyrifos, Quinalphos, Parathion  
b. Dimethyl – Methyl-parathion, Monocrotophos, Fenthion, Dimethoate 
c. S-Alkyl – Profenofos, Methamidophos  
4. Lipid solubility – Higher the lipid solubility 
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 Delayed onset, longer acting 
 Sudden release of compound resulting in sudden severe cholinergic crises and 
respiratory arrest 
 Fention, Dichlorfenthion, Parathion, Chlorpyrifos – more lipid soluble among 
the organophosphorus compounds 
 
 
Figure 4: Chemical structure of organophosphorus pesticides – A,B,C are diethyl, D is dimethyl 
and E,F are S-alkyl compounds; A,C,F are thions and D,E are oxons (3) 
 
TOXICITY AND CLINICAL MANIFESTATIONS 
These compounds inhibit the synaptic enzyme acetylcholinesterase (AChE) 
which breaks down acetylcholine leading to accumulation of acetylcholine at the 
synapses and overstimulation of muscarinic and nicotinic receptors of the central and 
autonomic nervous system and neuromuscular junction. AChE is an esterase enzyme 
that has two binding sites, namely the anionic and esteratic sites. OP compounds 
covalently react with the serine moiety in the estaratic site producing a serine-
phosphoester bond due to this nucleophilic attack. This inactivates the enzyme 
preventing esteratic cleavage of AChE and causes accumulation of acetylcholine at 
the nerve endings. Acetylcholine a neurotransmitter found in the neuromuscular 
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junction, pre-ganglionic autonomic nerves as well as the post-ganglionic 
parasympathetic nerves. This is similar to butyrylcholinesterase which is present in 
plasma. The acetylcholine accumulation leads to generalised, prolonged central and 
peripheral post-synaptic stimulation.(39) Nicotinic cholinergic receptor activation 
results in involuntary contraction of skeletal muscles manifested as fasciculations and 
complete depolarisation block which in turn causes flaccid paralysis. Muscarinic 
receptor activation activates the secretory glands resulting in the commonly described 
SLUDGE symptoms of organophosphorus poisoning which is composed of 
‗Salivation, Lacrimation, Urination, Diaphoresis, Gastrointestinal upset and Emesis‘. 
Other muscarinic effects include bronchorrhoea, bronchoconstriction and miosis along 
with bradycardia. The central nervous system effects of the accumulated acetylcholine 
include disorientation, anxiety and seizures succeeded by loss of consciousness with 
respiratory arrest.(40) Death may result due to cardiorespiratory arrest or due to 
prolonged seizures, especially in the nerve agents such as sabin and soman.(39,41) 
The severity of these clinical manifestations depend on several factors including dose 
ingested, onset of action of the compound, rate of absorption and stability of the 
formulation. The oxons which do not require conversion to active form will have 
faster action but for the thions, onset of toxicity will vary depending on the rate of 
their activation.  For example, parathion which gets activated rapidly will act faster 
than dimethoate which is a slow inhibitor of AChE as its conversion to omethoate, the 
oxon form, is slower.(42) The clinical profile of organophosphorus poisoning has 
been graded based on severity by Namba in his 1971 study on parathion and its 
manifestations as described below.(43)  
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ENZYME REACTIVATION AND OXIMES 
AChE inhibition caused by OPs last longer than that caused by Carbamates. 
Organophosphorus compounds react with the enzyme at the ester site and the bond 
stability is dependent on the molecular structure of the OP compound. Hydrolysis may 
occur spontaneously with methyl and ethyl compounds but may be hindered in 
compounds with larger alkyl groups which results in a phosphorylated enzyme which 
is inactive. Spontaneous reactivation of the enzyme occurs slowly with half-life of 0.7 
hours for dimethyl compounds and 31 hours for diethyl compounds. A process of 
‗ageing‘ is said to occur when one of the alkyl groups is removed from the phosphate 
group of the inactive enzyme, leaving a hydroxyl anion group attach to the 
phosphorous at the ester site. Once aged, It is left with a phosphate that is negatively 
charged and it cannot be further regenerated by a nucleophile with a negative charge 
such as oximes (as described in figure 2).(4,5) When there is a greater quantity of 
inactivated compound, such as in compounds with sow spontaneous regeneration, 
there is a higher rate of ageing. The rate of ageing is faster for dimethyl compared to 
diethyl compounds with half-life of 3.7 hours and 31 hours respectively resulting in 
therapeutic windows of 13 and 132 hours respectively. After 7 hours of poisoning, 
75% of enzyme is not reactivable in dimethyl OP poisoning. In case of S-alkyl 
compounds, There is almost immediate ‗ageing‘.(2)  
Oximes are nucleophilic compounds that react with and transfer the phosphoryl 
group from the enzyme to itself. (4) The basic oxime group catalyses the hydrolysis of 
the phosphodiester bond between the cholinesterase enzyme and the 
organophosphorus compounds and thereby frees the active site of the enzyme.(44) 
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They enhance the rate of reaction 2 described in the above figure 4 and reduce the 
amount of inactivated enzyme which is available for the ageing process. 
 
Figure 5: Reaction of OP with AChE (4) 
There are four main oximes which have been used in clinical trials and clinical 
settings – pralidoxime, obidoxime, Hl6, and Hlo7. Obidoxime is forty, nine, and three 
times more potent than Hl6, Hlo7, and pralidoxime, respectively.(45) More oxime is 
required to reactivate a dimethyl compound than a diethyl compound. Dimethyl 
compounds need 20 times more pralidoxime than obidoxime and diethyl compounds 
need 7 times more pralidoxime than obidoxime.(46) 
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Figure 6: Structural formulae of pralidoxime chloride and obidoxime chloride (47) 
 
SYNDROMES OF ORGANOPHOSPHORUS POISONING 
1. Acute cholinergic crises: Predominantly muscarinic symptoms, the severity of 
which is graded according to the scale by Namba, et al.(48) 
Namba grade                                                              Clinical presentation 
Namba 1 or Latent  No clinical manifestations 
 Assessment of severity is by measurement of serum 
cholinesterase level which will be inhibited by 10-50% 
 Namba II or Mild  The patient is able to walk but complains of dizziness, 
headache, nausea and vomiting, numbness of extremities, 
excessive sweating and salivation, abdominal cramps, 
tightness in chest or diarrhoea 
 Serum cholinesterase level is 20-50% of normal 
Namba III or Moderate                                      The patient is unable to walk and there is difficulty talking, 
generalised weakness, muscular fasciculation, and miosis. 
 Cholinesterase level is 10-20% of normal 
Namba IV or Severe                                           Unconsciousness, loss of pupil reflex to light and marked 
miosis, flaccid paralysis, muscular fasciculation, secretions 
from the mouth, moist rales in the lungs and nose, respiratory 
difficulty and cyanosis. 
 Serum Cholinesterase levels < 10% of normal. 
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2. Intermediate syndrome: Patients may develop neuromuscular junction failure 
after the cholinergic crisis ends and may have sudden respiratory arrest. 
Intermediate syndrome was defined during a prior study in our institution as 
proximal muscle weakness of grade 3 or less with extra-ocular, neck and 
respiratory muscles weakness developing after 72 hours of consumption of the 
organophosphorus compound, which may or may not require mechanical 
ventilation.(49) Several mechanisms have been postulated for the development of 
intermediate syndrome including neuromuscular junction dysfunction(50), late 
release of organophosphorus compounds from adipose tissue resulting in delayed 
paralysis(51) and lack of early oxime therapy resulting in persistent nicotinic 
effects.(52,53) Other postulates were oxidative stress-induced myopathy, 
desensitisation or down regulation of acetylcholine receptors and muscle 
necrosis.(54)  Methylparathion and monocrotophos were found to have high 
incidence of intermediate syndrome in a study conducted in India.(53) The usual 
presentation of intermediate syndrome is respiratory muscle weakness and 
treatment is mainly supportive till recovery which usually occurs between 3 to 12 
days. During this period of intermediate syndrome, patients may develop altered 
consciousness manifesting the clinical entity known as delayed organophosphate 
encephalopathy (DOPE) or ―CNS intermediate‖ in which patients have small 
miosed pupils.(55)  
3. Delayed manifestations: Patients with OP poisoning can have delayed 
manifestations such as peripheral neuropathy and neuropsychiatric manifestations 
in form of behavioural changes. 
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MANAGEMENT OF ORGANOPHOSPHORUS POISONING 
GENERAL MEASURES:  
Early therapy for organophosphate poisoning is known to be life-saving. 
Supportive management including maintenance of airway, breathing and circulation 
and decontamination are imperative parts of care.(56) Information on the type of 
poison must also be obtained to further guide management. Gastric lavage may be 
effective if done early after ingestion of the compound. Although there are no 
randomised controlled trials evaluating its benefit in OP poisoning, it has theoretical 
benefit and should be considered in all patients early in the course of admission after 
initial resuscitation measures.(57) Activated charcoal has shown to reduce the in-vitro 
adsorption of organophosphorus compounds(58), but this result was not replicated in-
vivo in a study done in Sri-Lanka where no benefit was found.(59) This discordance 
might be attributed to faster absorption of the compound into the blood and other 
factors such as large dose or late charcoal administration. At present, there is no 
evidence for administering charcoal in these patients.(3) 
ATROPINE: 
 The mainstay of specific therapy for OP poisoning remains anticholinergic 
agents with clinical data showing the efficacy of atropine in preventing respiratory 
failure. Atropine blocks the effects of organophosphorus compounds on muscarinic 
sites. Atropine is given in incremental doubling doses until the chest is clear and to 
maintain a heart rate of more than 80 beats per minute followed by an infusion.(60) 
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ROLE OF OXIMES IN ORGANOPHOSPHORUS POISONING 
Oximes show benefit in-vitro, in animal models and in accidental poisoning. 
The first trial showing the efficacy of oximes in organophosphorus poisoning was 
done in the 1950s on workers exposed to the compound.(61) Over the years, the 
results of various trials done to determine the efficacy of oximes in organophosphorus 
poisoning have been inconclusive. Few clinical trials have shown efficacy of oximes 
in the setting of mega-dose OP poisoning. Hence their role as a specific therapy for 
organophosphate poisoning remains controversial. 
WHO recommends that oximes may be used for the treatment of 
organophosphorus poisoning.(56) The previously used dose of pralidoxime of 1g of 
loading followed by repeat doses hourly in severe poisoning was replaced as it had 
been shown to produce sub-therapeutic levels of oxime. The alternative 
recommendation was 2g of loading followed by 500mg/hour infusion (30mg/kg bolus 
which is followed by 8mg/kg/hour continuous infusion)  to achieve pralidoxime levels 
in blood above 4mg/L.(62,63) Obidoxime dose recommended was 3mg/kg as slow 
intravenous infusion followed by 0.4mg/kg/hour. An uncontrolled study showed the 
benefit of pralidoxime in OP poisoning.(47) However, a retrospective study detailed 
the clinical outcomes in Sri Lanka before and after pralidoxime became available. It 
found that there was no significant difference when pralidoxime was added to atropine 
therapy.(64) Other retrospective trials also did not find any statistically significant 
benefit with pralidoxime therapy. There was no added benefit of oximes over the 
standard therapy with atropine along with adequate general measures, especially 
respiratory support.(64–66) However, one retrospective study noted the presence of 
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significant reactivability of the acetylcholinesterase enzyme associated with 
pralidoxime therapy although there was no significant clinical effect of the same.(66)  
 
 
Figure 7: Studies which were included in systematic reviews of oximes in organophosphorus 
poisoning (62) 
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The above figure 7 summarises the various trials, both retrospective and 
randomised, that have studied oxime therapy for poisoning due to organophosphorus 
compounds. Despite all the above trials not showing any benefit of oxime therapy, the 
results may have been confounded by other factors such as limitations of 
methodology, inadequate reporting and small sample sizes for all the studies. Many of 
the above studies did not follow the WHO guidelines for dosing of pralidoxime. Some 
of the studies used bolus doses of oximes instead of infusions and in some, there was 
no bolus dose given prior to start of infusion. Two studies have detailed the 
superiority of the WHO regimen consisting of 2g stat dose of pralidoxime followed by 
continuous infusion with lower rates of intermediate syndrome, requirement for 
mechanical ventilation and lower total atropine dose required compared to the 
repetitive bolus dose injection.(67,68) 
 Several systematic reviews have studied the effectiveness of pralidoxime with 
the same results as the individual trials with no significant statistical difference in 
mortality or other complications as shown in figure 8. In the review by Eddleston et 
al, it was further found that there was no benefit for oximes across different sub-
groups analyses including dimethyl and diethyl class of OPs, those presenting less 
than and more than 4 hours after admission and in those presenting with differing 
levels of severity.(69) 
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There may be several factors which have contributed to this apparent lack of 
in-vivo benefit including poor affinity of the oxime for the particular complex of OP 
with AChE, low dose or inadequate duration of treatment, time interval between 
Figure 8: Systematic reviews assessing the effectiveness of pralidoxime in organophosphorus 
poisoning (60) 
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poison ingestion and oxime administration, reinhibition of the reactivated enzyme due 
to the persistence of the poison in the patient and variable ageing times of different 
compounds. In view of the above factors and the additional confounding factors in 
each study, it was concluded that the above trials were insufficient to reach a 
conclusion regarding the usefulness of oxime therapy in OP poisoning.(4) 
 
TRIALS AT CHRISTIAN MEDICAL COLLEGE, VELLORE 
Two Randomised Control Trials done in our institution did not show any 
benefit from pralidoxime therapy. The first trial included 72 patients and compared 
low-dose(1g bolus) against high-dose pralidoxime (12g as infusion over 4 days) and 
showed worse outcomes in the second group with higher rates of ventilator 
requirement and intermediate syndrome, although these event rates were not 
statistically significant.(70) However, a sub-group analysis showed lower incidence of 
intermediate syndrome in those whom pralidoxime was administered within 12 hours 
of ingestion indicating benefit for early therapy. The second trial was placebo-
controlled with 110 patients getting high-dose pralidoxime (12g over 3 days). This 
also showed higher mortality rates in the high-dose group as well as higher rates of 
ventilation.(71) A systematic review of four trials including the above two trials 
questioned whether therapeutic levels of pralidoxime were reached as bolus dose was 
not given and the current WHO-recommended dose was not implemented during the 
time period of both the studies.(4) The ‗harm‘ that occurred in the second study may 
be related to a selection bias as the sicker patients may have been in the high-dose 
group.  
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CONTROVERSY REGARDING OXIME THERAPY 
The WHO recommendation of pralidoxime and obidoxime dose was based on 
an in-vitro and animal study which determined the dose of pralidoxime required to 
reach therapeutic levels rapidly and to sustain a high concentration.(72) This dose 
may, however, represent an under dosing in patients with mega-dose OP poisoning 
due to the variable kinetics displayed by the different compounds. The complete 
therapeutic potential of pralidoxime may not be exploited at this dose. In cases of 
severe OP poisoning with large doses, there may be rapid re-inhibition of the 
reactivated enzyme especially in the initial few days after poisoning which may render 
pralidoxime ineffective particularly when it is administered at lower doses.(73)  
A Cochrane review also showed insufficient evidence for the use of 
oximes.(74) It, however, included only one RCT with the WHO recommended dose 
consisting of 30mg/kg bolus followed by 8mg/kg/hour infusion which was conducted 
in Sri Lanka and randomised 235 patients to either receive pralidoxime or saline 
placebo. The primary outcome of mortality was not significantly different between the 
two groups. The levels of pralidoxime were also measured and there was no difference 
in levels between survivors and those who died. Red cell AChE levels were measured 
and there was in-vitro reactivation of enzymes inhibited by OPs belonging to  diethyl 
class but not dimethyl class of compounds.(69)  
Due to these multiple in-vivo studies which have failed to show sufficient 
benefit from oxime therapy, their use had been discontinued in our institution. The 
Cochrane analysis and systematic reviews have shown that the results from these trials 
may have been affected by several factors including timing of administration of 
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oximes, the dose of pralidoxime and type of organophosphorus compound. 
Organophosphate poisoning is a heterogeneous clinical condition, both in the variety 
of compounds, amount of poison ingested, the variability of time to presentation, 
differences in decontamination, absorption and metabolism.  
It is possible that a sub-group of patients with organophosphate poisoning may 
benefit from oxime therapy.  Eddleston et al postulated that there may have been a 
benefit from oximes in a sub-group of patients which may have been masked by the 
ineffectiveness in the majority. It was suggested that there may be a role for selective 
administration of oximes for certain clinical settings of organophosphorus 
poisoning.(42,69) 
 
PLASMA BUTYRYLCHOLINESTERASE (BChE) LEVELS 
 The above postulate of selective administration of oximes led to several studies 
to determine optimal administration of oximes in certain clinical setting with only 
selected organophosphorus compounds. In-vitro trials have attempted to determine the 
reactivation of the cholinesterase enzymes after application of oximes in the 
laboratory. It was attempted to apply these results later to clinical care of the patients 
with organophosphorus poisoning. Most in-vitro trials on oxime efficacy have been 
conducted with plasma butyrylcholinesterase (BChE). Reactivation potential of 
butyrlcholinesterase and acetylcholinesterase is defined as the difference between 
oxime-reactivated enzyme and unreactivated enzyme activity. This reactivation 
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potential and subsequent clinical consequences of the same have not been sufficiently 
analysed.  
A study done in our institution showed that plasma BChE activity correlated 
with the severity of OP poisoning and that reactivation potentials were lower for 
patients who had developed intermediate syndrome and those with greater severity. 
However, there was no increase in BChE levels in those who had received oximes 
prior to admission.(49) As expected the BChE levels showed a decremental response 
as the time after poison ingestion increased. This study showed that the BChE values 
may correlate well with the severity of poisoning in clinical settings and the temporal 
profile may correlate with the clinical course. However, the pathophysiology of OP 
poisoning is based on the inhibition of Acetylcholinesterase (AChE) in the synapses. 
Plasma BChE is being used as an indirect marker of enzyme activity in place of AChE 
and is not directly involved in the pathogenesis of toxicity in organophosphorus 
poisoning. A study showed that the reactivation of BChE by pralidoxime in Sri 
Lankan patients with OP poisoning was variable and was not sustained.(75) 
Pralidoxime reactivated diethyl compounds at a 2g bolus dose but not with the 1g 
bolus dose and this reactivation was poorly sustained. There was no improvement in 
enzyme activity in dimethyl compound poisoning. There was significant variability in 
individual responses of cholinesterases when given pralidoxime. Therefore plasma 
cholinesterase levels may not be sufficient to assess the efficacy of oximes. Its 
usefulness is also determined by the type of OP compound as a level of <600mU/ml 
on admission was highly sensitive for chlorpyrifos but more specific for dimethoate 
poisoning.(76) 
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Questions have arisen about the appropriateness of butyrylcholinesterase 
activity as a test of oxime efficacy in view of the conflicting findings of several 
studies determining the correlation of BChE and its reactivation with the synaptic 
AChE levels. Pralidoxime at doses of 100mcM and Obidoxime at dose of 175mcg/ml 
have been shown to reactivate BChE which had been inactivated by parathion, 
paroxon and chlorpyrifos.(77,78) However, two more in-vitro studies showed 
contradictory findings and found no reactivation of BChE with either pralidoxime or 
obidoxime in parathion and methylparathion poisoning.(79,80) This led to the 
recommendation that BChE was an inappropriate test for studying the efficacy of 
oximes in organophosphorus poisoning.(79) The main utility of BChE lies in 
diagnosis of OP poisoning in doubtful cases and to monitor OP elimination from the 
body as the liver synthesises BChE continuously in contrast to AChE which requires 
erythropoiesis for regeneration. Therefore, once the inhibitory organophosphorus 
compound is eliminated from the bloodstream, there should be rapid rise in 
butyrylcholinesterase levels which would signify the culmination of the cholinergic 
crisis.(81) 
 
ERYTHROCYTE ACETYLCHOLINESTERASE (AChE) LEVELS 
It was suggested that measurement of RBC AChE would be a better marker for 
determining the severity of OP poisoning and to further study the efficacy of oximes 
than BChE. AChE in mammals is coded by a single gene and therefore, the structure 
of the RBC-AChE should be similar to that found in the synapses. RBC-AChE is, thus 
used as a surrogate marker for the activity of the synaptic enzyme and is expected to 
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react similarly with the organophosphorus compound.(82) RBC-AChE has been 
shown to correlate better with neuromuscular transmission. A level of more than 30% 
was found to correlate with normal muscle function and precludes the use of atropine 
whereas a level of less than 10% correlated with severe neuromuscular transmission 
reflected by a decremental response.(83) In a dynamic in-vitro muscle model, the 
erythrocyte AChE level was found to correlate well with the muscle membrane AChE 
reflecting that RBC-AChE is a good parameter for the studying the mechanisms of 
Organophosphorus-related inhibition, ageing kinetics as well as reactivation kinetics 
both spontaneously and with oxime therapy. These in-vitro results were also applied 
to parathion poisoned patients for study and there was favourable correlation between 
the clinical data and the laboratory findings.(84) In patients with parathion poisoning, 
the cholinergic signs resolved after the RBC-AChE levels rose to more than 
20%.(46,85) However, RBC-AChE is not a perfect test and there are certain 
disadvantages to it use in clinical practice and research settings. RBC-AChE levels 
recover less rapidly than muscle function recovery and may not be a good marker of 
improvement. This is because acetylcholine is reproduced only be production of new 
RBCs and this regeneration is a slow process occurring at a rate of 1% per day of total 
AChE level. It takes approximately 5 weeks for the AChE levels to return to normal 
after OP poison consumption.(86) The assays are also more cumbersome as they have 
to be done on whole blood which is immediately cooled after dilution and inhibitor 
must be added to block BChE activity. This should be done to block the on-going 
reactions between the organophosphorus compound, acetylcholinesterase and oximes 
which would continue if the sample was left even for few minutes at room 
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temperature. They are also sensitive to the level of oxime, the substrate and pH.(3) To 
be reliable, the sample must be collected and cooled and diluted rapidly to get 
accurate results. In many cases, it was also found that the levels of AChE did not 
uniformly conform with the clinical picture which may be related to the variable 
distribution and excess AChE distributed across the different tissues of the body.(87) 
 
TRIPLE CHOLINESTERASE TEST 
Certain studies have suggested the apparent lack of efficacy of oxime therapy 
may be due to sub-therapeutic doses of oximes and have propounded that oxime 
therapy must be continued as long as there is reactivation potential in the inhibited 
acetylcholinesterase enzyme. This led to the concept of determination of reactivation 
potential of the enzyme to guide oxime therapy. Many of the above clinical studies 
showing ineffectiveness of oxime therapy were limited by the under dosing of oximes 
in the trial. Based on theoretical considerations and in-vitro and clinical findings, it 
was concluded that oximes must be administered as long as there was reactivability of 
the acetylcholinesterase enzyme and until definitive and complete clinical 
improvement.(7,73) Thiermann et al studied the use of such a regimen of oxime 
therapy with objective parameters consisting of the following tests: RBC-AChE, 
reactivability of RBC-AChE ex vivo, plasma ChE activity, AChE inhibiting 
compounds and concentrations of obidoxime and atropine in patient‘s plasma. A bolus 
dose of obidoxime followed by infusion was administered and levels of 10-20mM 
were attained in accordance to the previous kinetic studies.(6,7) Obidoxime therapy 
was effective when administered early especially in parathion poisoning. Enzyme 
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reactivation was almost complete when obidoxime was administered within one hour 
after consumption of the compound. It was not effective for patients with 
oxydemetonmethyl poisoning. This study, however, was limited by a small sample 
size as it included only 5 patients.(7) The group involved in the above study 
postulated that the above advanced laboratory monitoring system determining the 
cholinesterase status of the patient can be used to effectively predict and follow-up the 
clinical course in patients with organophosphorus poisoning and also guide the 
rational use of oxime therapy. Based on the data from these tests, oxime therapy could 
be individualised on a case-to-case basis.(82)  
The triple cholinesterase test is a laboratory system which was devised to 
determine the cholinesterase status of the patient and consists of the following battery 
of investigations: 
1. Plasma Butyrylcholinesterase 
2. RBC Acetylcholinesterase 
3. Reactivation potential of RBC-AChE ex-vivo  
 Defined as the difference between the enzyme activity after reactivation by 
oximes and the enzyme activity prior to oxime administration 
 Can be studied by measuring RBC-AChE levels after incubating whole blood 
with obidoxime 
4. Inhibitory potential of patient’s plasma  
 Reflects the presence of poison in the plasma of the patient but does not 
involve identification of the organophosphorus compound 
 Can be determined by incubating the patient‘s plasma with standardised RBC-
AChE derived from a healthy donor 
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This cholinesterase status testing was done in animal experiments on pigs poisoned 
with sarin and oximes were administered according to this status. A rapid rise in RBC-
AChE activity was noted with prompt clinical resolution of symptoms and signs. 
Neuromuscular transmission was also studied to confirm recovery as an objective 
clinical parameter especially when the AChE was completely aged and it was difficult 
to determine the end of the cholinergic crisis. This study suggested that oximes should 
be given as early as possible in all patients with OP poisoning to be effective and their 
effects can be assessed by the triple cholinesterase test status. It affirmed the findings 
of the previous study and recommended continued oxime administration till 
reactivation was possible and there was absence of inhibitory substance in the 
patient‘s plasma.(8,88) 
The assessment of cholinesterase status as a guide to oxime therapy has not been 
done on a large number of patients with organophosphorus poisoning. As earlier 
suggested, there may be a sub-group of patients who may benefit from oxime therapy. 
The diagnostic challenge is to identify this group of patients. By study the temporal 
profile of the triple cholinesterase status in different clinical settings and correlating 
with the patient and organophosphorus compound characteristics, it may be possible 
to identify the clinical characteristics of the sub-group of patients with good enzyme 
reactivability with oximes. Identifying such a group of patients, may allow for a 
tightly controlled clinical trial to evaluate the benefit of oximes in patients who may 
potentially benefit from this treatment. We attempt to validate the triple cholinesterase 
test for point-of-care testing to determine the characteristics of the sub-group of 
patients in whom oxime therapy could potentially be useful.  
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JUSTIFICATION 
The study consists of two parts as follows: 
A. To study the role of triple cholinesterase test in the management of 
Organophosphorus (OP) poisoning 
Organophosphorus insecticides are familiar household products which are the 
most common suicidal agents used in Asian countries. While early treatment is known 
to be life-saving, specific therapy for organophosphate poisoning still revolves around 
anticholinergic agents which however cannot revive the acetylcholinesterase enzyme 
that is inhibited by the organophosphorus at the synapses. Oximes such as 
Pralidoxime and Obidoxime have been shown to reactivate the cholinesterase enzyme 
which had been phosphorylated by binding to the OP molecule with obidoxime being 
more potent than the other oximes. However, their role in routine management of OP 
poisoning remains controversial. Several in-vitro studies have shown their potency in 
reactivating the cholinesterase enzyme. However, the same results have not been 
replicated in many clinical studies. Furthermore, their ability to reactivate the enzyme 
depends on several factors that affect the aging of the OP-enzyme compound such as 
timing of administration, the type of organophosphorus compound, the quantity of the 
compound, pH and temperature. Due to these reasons, oxime therapy has not been 
universally accepted as part of routine management. Studies done in recent times have 
suggested that there may be certain sub-groups of patients in whom oximes would be 
beneficial. A new concept of determination of cholinesterase status to guide oxime 
35 
 
therapy has also been put forth wherein the oxime is administered as long as there is 
reactivation of the AChE in-vitro. This study aims to answer the following questions: 
 1. What is the in-vitro potential of obidoxime to reactivate OP inhibited 
cholinesterase enzymes? 
 2. Can a battery of tests including RBC acetylcholinesterase (AChE), Plasma 
butyrylcholinesterase (BChE) and enzyme reactivating potential of obidoxime in-vitro 
be applied at point-of-care for patients with OP poisoning to determine their suitability 
for oxime therapy? 
 3. In what clinical situations, would oxime therapy be useful? 
 
B. Changing trends in the profile of poisoning presenting to a tertiary care 
centre in South India. 
 During another toxicological study in the same centre on plant poisoning, it 
was found that there was sharp decline in the number of plant poisoning cases. By 
analysing the poisoning database of this hospital, it would be possible to determine the 
changing profile of adult poisoning presenting to our hospital in relation to the major 
classes of poisoning, their epidemiology and the outcomes. This would help in 
toxicovigilance activities at a regional level. 
 
36 
 
METHODOLOGY – (A) TRIPLE CHOLINESTERASE TEST 
IN ORGANOPHOSPHORUS POISONING: 
SAMPLE AND SETTING 
 This study was conducted in the period between April 2015 and August 2015 
in Christian Medical College, Vellore. All patients who presented to adult emergency 
department with organophosphorus poisoning fulfilling the inclusion criteria and 
willing to participate in the study were included in the study. The procedures of the 
study were explained in detail to the participants and their close relatives and they 
were provided with an information sheet about the study (Annexure 1). Participants 
were included only after obtaining written consent either from the patient directly or 
from their close relative if the participant was otherwise indisposed (Annexure 2). 
Consent was obtained in the participants‘ native language. In case of consent obtained 
from relative, re-consent was obtained from the participant after recovery. For 
participants between the ages of 15 and 18 years, consent was obtained from the legal 
guardian and assent was taken from the participant. 
STUDY DESIGN 
 This is a prospective cohort study done as pilot study in patients presenting 
with organophosphorus poisoning to evaluate the triple cholinesterase test. 
SAMPLE SIZE 
There are no studies that have correlated cholinesterase studies to the clinical 
profile. Hence it was not possible to calculate the sample size for the clinical study. So 
after discussion with our collaborators, we decided on sample size of 30 for a pilot 
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study. Based on previous studies we expect an adequate distribution of clinical factors 
that may determine oxime reactivability: 50% dimethyl and diethyl OP compounds; 
20% with prior oxime use; 40% who will present in less than 6 hours after ingestion 
and 60% with severe poisoning and 40% with mild and moderate poisoning. 
PARTICIPANTS 
All patients presenting to adult emergency department in CMC, Vellore within 
30 hours of ingestion of organophosphorus compound were included in the study. The 
following were included as the case definitions for organophosphorus poisoning: 
1. Patients who present with history of pesticide poisoning with an identified OP 
compound. 
2. Patients who present with history of pesticide poisoning with typical toxidrome of 
organophosphate poisoning, and low BChE levels (<3000 U/L). 
3. Patients who present without a history of pesticide poisoning but with typical 
toxidrome of  OP poisoning and low BChE levels (<3000 U/L)  
Those presenting after 30 hours of OP consumption and those less than 15 years of 
age were excluded from the study. Persons who had consumed mixed compounds of 
organophosphorus with pyrethroids were not excluded. Pregnant women and children 
between 15 and 18 years of age were also included as OP poisoning can occur in any 
person and as this is an observational study with no harm expected to the patients. 
MEASUREMENTS – DATA AND SAMPLE COLLECTION 
 Data collection was done by the principal investigator at patient presentation to 
CMC, Vellore followed by serial assessment 12 hours later and subsequently once 
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daily between 6-8 PM till discharge. The clinical data was documented in the patient 
proforma (Annexure 3) by the principal investigator. The following details were noted 
specifically 
1. Compound characteristics – class, quantity and combination with pyrethroids 
2. Time to presentation to CMC, Vellore 
3. Treatment elsewhere – Gastric lavage, Atropine and Pralidoxime received including 
the doses 
4. Severity at presentation (by Namba scale) 
5. Outcomes – Dose of atropine required and duration, Mechanical ventilation and 
duration,  Intermediate syndrome and duration, Need for ICU admission and duration 
Samples for triple cholinesterase test were collected at admission not later than 
30 hours after OP consumption followed by repeat sample 12 hours later and 
subsequently once daily at 12 PM for 5 days from poison consumption. The protocol 
for data and sample collection has been detailed in Annexure 4. 
 
DETERMINATION OF CHOLINESTERASE STATUS  
All patients had the following investigations done on the samples collected as 
mentioned above: 
1. RBC-AChE activity 
2. Plasma BChE activity 
3. RBC-AChE reactivation potential with obidoxime ex-vivo 
4. Inhibitor activity of patient‘s plasma on control RBC-AChE 
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Reference standard used in our lab is measurement of plasma BChE and RBC-
AChE. We use modified Ellman assay for detection of cholinesterase levels in our lab. 
After recruitment into the study, venous blood samples were collected from the patient 
and 2 ml of blood was added to a purple EDTA tube. For RBC AChE analysis, from 
the collected blood samples, 200 microlitres of blood was measured using a pipette 
and diluted (20 times) in 4 ml of cold normal saline (at 40 degree C) to prevent 
hemolysis, which was then well mixed and stored in -20 degree Celsius in the 
refrigerator within 5 minutes. The blood samples were sent to laboratory in batches at 
the end of 5 days for each patient. The remaining sample in the EDTA tube was then 
sent for BChE analysis immediately to the lab. Both the assays used the same 
principle measured through an automated assay. This method measures hydrolysis of 
the substrate acetylthiocholine (ATCh) by either BChE or AChE to yield acetate and 
thiocholine. The latter product reacts with 5, 5‘-dithiobis-2-nitrobenzoic acid to 
produce a yellow-coloured acid anion (5-thio-thionitrobenzoic acid) that can be 
measured with a spectrophotometer. The results were expressed as micromoles per 
minute per milliliter (μmol/min/mL) and adjusted for haemoglobin absorbance. 
STANDARD OPERATING PROTOCOL OF TRIPLE CHOLINESTERASE 
TEST 
The determination of the cholinesterase status was done according to the 
standard operating protocol used by Thierman and Worek  et al in their previous study 
and was discussed with them. All laboratory measurements were based on the 
recommendations of Eyer et al and standardised for our laboratory analysers.(88,89)  
The complete details of the test and measurements are detailed in Annexure 5. 
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DATA ANALYSIS AND STATISTICAL METHODS 
STATISTICAL METHODS 
Out of 36 patients screened for OP poisoning, 6 were excluded, 4 as they 
presented after 30 hours and 2 as they were later found to be due to carbamate 
poisoning. 30 patients were included for the final analysis. The primary outcome 
involved the comparison of temporal profile of RBC acetylcholinesterase, 
reactivability and plasma inhibitory activity on AChE (mean absolute value on Day 1, 
day 3 and day 5) in the following groups: 
1. Severity of poisoning (mild vs. moderate/severe) 
2. Dimethyl vs. Diethyl compounds 
3. Mechanical ventilation vs. no mechanical ventilation 
4. Intermediate syndrome vs. no intermediate syndrome 
5. Prior exposure to oximes vs. oxime-naïve patients 
The secondary outcome was the description of clinical characteristics of (1) 
Patients who have RBC AChE reactivability at admission and for the first 3 days and 
(2) Patients who have persisting plasma cholinesterase inhibitory activity.  
In view of the small number of patients included in this pilot study, non-
parametric statistical tests such as Mann-Whitney U test and Kruskal-Wallis tests 
were used to analyse the data and to determine the significance level of the differences 
among the groups.  
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METHODOLOGY – (B) STUDY OF POISONING PROFILE 
USING THE POISON DATABASE: 
Medicine unit 1 in CMC, Vellore has been functioning as a poison control 
centre and prospectively collecting the poisoning data base from 2009. (AC approval 
for the establishment of the Poison control centre and development of the CMC poison 
database – Min. No. 5-a(4):2-15 dt. 19.02.2015) We have reviewed over 2300 
poisoning proformas collected by the Poison centre between 2009-2014 and obtained 
data relevant for this study based on data abstraction form (Annexure 6). We verified 
data where required from inpatient discharge summaries and outpatient scanned charts 
from the electronic record system. The following details of interest for the study were 
collected from the poisoning proforma: 
1. Demographic details – age, sex, occupation 
2. Mode of poisoning – Accidental /Deliberate self-harm  
3. Poison details (Chemical name and Class of compound)  
4. Status at admission – Casualty/Ward admission/ICU admission  
5. Outcome – Dead/Alive/Discharge against medical advice 
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FUNDING AND APPROVAL 
SOURCE OF FUNDING 
 A FLUID research grant was approved from the institution for the purpose of 
this study. The funds were used for the cholinesterase status assays and for 
procurement of the reagents and obidoxime. 
INSTITUTIONAL RESEARCH BOARD APPROVAL AND 
ETHICAL CONSIDERATIONS 
 The research proposal for the triple cholinesterase test was discussed by the 
Institutional Review Board in 2015 and approval was obtained [IRB Min. No. 9463 
dated 05.06.2015].  There were no ethical issues related to this study. Institutional 
review board approval was obtained for the procedures. The study on the poison 
database was also discussed by the IRB and approval was obtained [IRB Min. No. 
9507 dated 24.06.2015]. 
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RESULTS – (A) TRIPLE CHOLINESTERASE TEST IN 
ORGANOPHOSPHORUS POISONING 
DEMOGRAPHIC CHARACTERISTICS  
 30 patients, 15 years of age or older, admitted to adult emergency department 
with organophosphorus poisoning within 30 hours of consumption were included in 
the study. The mean age (±S.D) was 28.4 years (±11.82 years) with a range of 15-
64 years. These patients were recruited between April 2015 and August 2015. 
Out of 30 patients, 14 were male and 16 were female. Of the female patients, 
one patient was pregnant and in the 2
nd
 trimester of pregnancy. 16 out of 30 
(53.3%) patients were uneducated and 24 (80%) were occupied in unskilled 
labour. (Table 1) 
COMPOUND CHARACTERISTICS  
 Out of 30 patients, the compound was not identified in 4 patients and the case 
ascertainment criteria used was patient presenting with history of pesticide poisoning 
with typical toxidrome of OP poisoning and with low BChE. Among the 26 cases, in 4 
cases, the leaflet was brought and in the remaining 22 cases, the bottle of pesticide 
was brought by the patient‘s relatives.  
 The most common compound used was monocrotophos accounting for 5 cases 
(16.7%). There were 4 cases each of dimethoate, profenofos and triazophos. The other 
compounds accounted for only one or two cases. 6 of the compounds had pyrethroids 
mixed with the OP, cypermethrin in 4 cases and deltamethrin in 2 cases. The most 
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common combined formulation was with chlorpyrifos and triazophos. The OP 
compounds were further categorised based on their chemical nature and dimethyl 
compounds accounted for 12(40%) of all OP poisonings and diethyl compounds for 
10(33.3%).  The S-alkyl compound used was profenofos accounting for 4(13%) of 
cases. (Table 1) 
Table 1: Patient and compound characteristics of OP poisoning cases 
Baseline characteristics Details (n=30) 
Identified OP 26 
Age (years) ± S.D. 28.4  ± 11.8 
Male, n(%) 46.7% (n=14) 
Compounds (in number of patients) Monocrotophos – 5 
Dimethoate – 4 
Profenofos – 4 
Triazophos – 4 
Chlorpyrifos – 2 
Quinalphos – 2 
Phorate – 2    
Dichlorvos, Methylparathion, Malathion – 1 each 
Compound type Dimethyl – 40% (n=12) 
Diethyl – 33% (n=10) 
S-Alkyl – 13% (n=4) 
Pyrethroid combination with OP 20% (n=6) 
4 – cypermethrin 
2 – deltamethrin 
 
TREATMENT ELSEWHERE PRIOR TO PRESENTATION 
 Of the 30 patients, 20 had received treatment elsewhere prior to presentation. 
The mean time interval between consumption and first medical contact was 2.05 hours 
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(± S.D 2.01). The time interval between consumption and presentation to CMC, 
Vellore was 6.6 hours (± S.D 5.84) ranging from 1 hour to 29 hours. 18 patients had 
received gastric lavage elsewhere prior to admission. 17 received atropine prior to 
presentation with doses ranging from 2 ampules to 20 ampules and with dose given 
being unknown in 10 cases. Pralidoxime had been given in 6 patients. In 2 of these 
patients, the dose given had been documented to be stat doses of 2g and 0.5g and 
among the others, the dose of PAM given was unknown. 4 patients had been intubated 
before admission here. 
TOXIDROME FEATURES AT PRESENTATION 
 The clinical symptoms at presentation are summarised in the table 2 below 
Table 2: Toxidrome features present at admission in the OP poisoning patients 
Toxidrome present Number of patients(%) 
Salivation 27 (90%) 
Lacrimation 6 (20%) 
Diaphoresis 9 (30%) 
Urination 9 (30%) 
Defecation  3 (10%) 
Vomiting 27 (90%) 
Seizures 3 (10%) 
Breathlessness 8 (26.7%) 
Altered sensorium 9 (30%) 
  
 The clinical signs at presentation and the overall severity according to the 
Namba scale are represented in the table 3 below 
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Table 3: Clinical signs present at admission in the OP poisoning patients 
Clinical signs Number of patients with % (or Mean ± S.D) 
GCS, n(%) 
15/15 
<10/15 
 
16 (53.3%) 
7 (23.5%) 
Pupil size, n(%) 
Pinpoint 
Dilated 
Normal (2-5mm) 
 
11 (36.7%) 
3 (10%) 
16 (53.3%) 
Heart rate, mean (± S.D) 102.53 (± 19.48) beats per minute 
Blood pressure, mean (± S.D) 110 (±16) / 70 (±10) mm Hg 
Respiratory rate, mean (± S.D) 
Mean RR 
Intubated 
Gasping 
 
23 (±6.5) per minute 
3 (10%) 
3 (10%) 
O2 saturation, mean (± S.D) 93 (± 8.8) %   
Blood sugar, mean (± S.D) 174.3 (± 56.6) mg% 
Fasciculations present, n(%) 8 (26.7%)  
Single breath count, mean (± S.D) 
Mean 
Could not be assessed 
 
13 (±12) counts 
8 (26.7%) 
Neck holding time , mean (± S.D) 
Mean  
Could not be assessed 
 
16 (± 18) seconds 
6 (20%) 
Severity (Namba scale), n(%) 
Latent 
Mild 
Moderate 
Severe 
 
0 
11 (36.7%) 
7 (23.3%) 
12 (40%) 
CLINICAL OUTCOMES  
 The overall clinical outcomes including intermediate syndrome, ICU 
admission, mechanical ventilation and dose and duration of atropine are summarised 
in the table 3 below. 
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Table 4: Clinical outcomes of the OP poisoning patients 
Clinical outcome Number of patients with % (or Mean ± S.D) 
Intermediate syndrome, n(%)  
Present 
Duration 
 
10 (30%) 
7.7 (± 4.9) days 
ICU admission, n(%) 
Present 
Duration 
 
17 (56.7%) 
8 (± 5) days 
Mechanical ventilation, n(%) 
Present 
Duration 
 
17 (56.7%) 
6.9 (± 4.5) days 
Tracheostomy required, n(%) 3 (10%) 
Infective complications present, n(%) 
VAP 
Bacteraemia 
10 (33.3%) 
9 (30%) 
2 (6.6%) 
Low GCS, n(%) 11 (36.6%) 
Atropine 
Required, n(%) 
Dose, mean (± S.D.) 
Duration, mean (± S.D.) 
 
28 (93.3%) 
243 (± 406) mg 
3 (± 1.3) days 
Hospitalisation duration, mean (± 
S.D.)  
9.3 (± 7.1) days 
Death, n(%) 
(Causes of death) 
3 (10%) 
(2 – Infection, 1 – Ventilator and airway problems ) 
 
CALCULATION OF AChE LEVELS 
 AChE level was calculated based on the Ellman method as described in the 
methodology and expressed as μmol/min/μmol Hb. AChE value was done on 20 
controls and 18 patients who had consumed pesticides which were not OP compounds 
or carbamate compounds. The median of the AChE values of this group was used to 
calculate the normal level which was found to be 16.18 μmol/min/μmol Hb (IQR 
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12.74–22.71). All subsequent AChE calculations of the patients including the baseline 
(pre-oxime) and pots-oxime levels were expressed in their absolute values and also in 
terms of a percentage of the normal AChE level. 
 
DEFINITION OF SIGNIFICANT REACTIVATION 
 Previous studies based on neuromuscular transmission in OP poisoning by 
Thiermann et al had shown that at a level of AChE less than 10% of normal, 
neuromuscular transmission was severely disturbed and this level was noted to 
indicate urgent need for mechanical ventilation. Levels above 30% did not have 
significant disturbance of transmission. Levels in between were associated with 
moderate poisoning.(8) Based on this study, significant reactivation was said to have 
occurred if the AChE, which was less than 30% at baseline, was reactivated to more 
than 30% after addition of obidoxime to the sample. 
 
BASELINE AChE LEVEL AND CLINICAL CHARACTERISTICS  
 The 30 patients underwent serial blood sampling for 5 days or up to discharge. 
AChE, obidoxime induced reactivated AChE and inhibitor activity performed on 
serial samples. The patients were divided into 3 groups based on their baseline AChE 
levels (Table 5). The groups were classified based on studies on the baseline AChE.  
1. Group I – baseline AChE level < 10% of normal (5 patients) 
- Severe inhibition of AChE; likely impairment of neuromuscular transmission 
2. Group II – baseline AChE level 10-30% of normal (13 patients) 
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- Moderate inhibition of AChE; likely impairment of neuromuscular transmission 
3. Group III – baseline AChE level >30% of normal (12 patients)  
- Mild inhibition of AChE; likely normal neuromuscular transmission 
Table 5: Clinical characteristics of groups according to baseline AChE level at admission 
  Group I – AChE 
<10% of normal 
n=5  
Group II – AChE 
10-30% of normal 
n=13  
Group III – AChE  
>30% of normal 
n=12  
p value 
Lag time to 
presentation to CMC 
– hours (±SD) 
      11.22(10.68)       7.11(4.33)        4.13(3.88) 0.503 
Prior oxime, n(%) 1(20%) 2(15.4%) 3(25%) 0.157 
Compounds, n(%) 
dimethyl 
diethyl 
 
3(60%) 
0 
 
4(30.8%) 
6(46.1%) 
 
5(41.7%) 
4(33.3%) 
0.080 
 
 
Severity, n(%) 
mild 
moderate 
severe 
 
0 
1(20%) 
4(80%) 
 
3(23.1%) 
4(30.8%) 
6(46.1%) 
 
8(66.6%) 
2(16.7%) 
2(16.7%) 
0.002 
 
 
Intermediate 
syndrome, n(%) 
3(60%) 5(38.5%) 2(16.7%) 0.066 
 
IS duration – days 
(±SD) 
9.3(7.5) 8.2(4.2) 4.0(1.4) 1.00 
Mechanical 
Ventilation, n(%) 
5(100%) 8(61.5%) 4(33.3%) 0.010 
 
Ventilation 
duration – days 
(±SD) 
8.0(6.0) 7.5(4.1) 4.2(2.9) 0.724 
 
Atropine dose (mg) 417.18 278.55 91.74 0.117 
Atropine duration 
– days (±SD) 
3.2(1.3) 3.3(1.5) 2.2(1.4) 0.924 
Hospitalisation 
duration – days (±SD) 
12.8(10.2) 10.5(8.2) 6.4(2.1) 0.503 
Death, n(%) 1(20%) 2(15.4%) 0  
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The comparison of patients with severe inhibition < 10% compared to 
moderate inhibition 10-30% and no inhibition > 30% showed that patients with more 
inhibition had greater rate of severe poisoning (p=0.002), mechanical ventilation 
(p=0.01), intermediate syndrome, atropine dose and duration of intermediate 
syndrome, mechanical ventilation and hospitalisation although the latter outcomes did 
not show statistical significance between the three groups. Overall, Table 5 shows that 
the baseline AChE level correlates with the clinical profile and that patients with 
severe inhibition of AChE have more severe clinical presentation with poorer 
outcomes than those with higher AChE levels. 
 
TEMPORAL PROFILE OF AChE LEVEL AND CORRELATION WITH 
SEVERITY  
 The temporal profile of AChE among the severity groups (according to Namba 
scale) was assessed. The mean AChE value at presentation for the mild poisoning 
group was 75.92% of normal and was significantly higher than mean AChE of the  
moderate and severe poisoning group of 34% (p=0.020).  The temporal profile of 
AChE in the mild poisoning group showed mild inhibition throughout the first 5 days 
compared to moderate and severe poisoning groups which had sustained inhibition 
throughout the duration of the study period. The temporal profiles of the moderate and 
severe poisoning groups were comparable with no significant difference. (Figure 9) 
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Figure 9: Temporal profile of AChE levels according to severity. The mild group had 11 
patients, the moderate group 7 patients and the severe group had 12 patients. 
 
AChE TEMPORAL PROFILE AND INTERMEDIATE SYNDROME  
AND MECHANICAL VENTILATION  
 There were 10 patients who developed intermediate syndrome and the temporal 
profile of their AChE levels was compared to that of the 20 patients who did not 
develop intermediate syndrome. The figure 10 below shows that the AChE levels of 
the intermediate syndrome group remain persistently inhibited compared to those who 
did not develop intermediate syndrome. The difference in baseline AChE in patients 
with intermediate syndrome compared to those who did not develop intermediate 
syndrome tended towards significance (p=0.074) and was significant on day 2 and 3. 
 Similar pattern was seen in the 17 patients who required mechanical ventilation 
compared to the 13 patients who did not require ventilation (Figure 11). The 
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difference in baseline AChE in patients who required mechanical ventilation 
compared to those who did not was significant (p=0.031) 
 
Figure 10: Temporal profile of AChE levels among patients who developed intermediate 
syndrome (n = 10) compared to those who did not develop intermediate syndrome (n = 20) 
 
 
Figure 11: Temporal profile of AChE levels among those who required mechanical ventilation 
(n = 17) compared to those who did not require mechanical ventilation (n = 13) 
stat 12 hours day 2 day 3 day 4 day 5
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AChE LEVELS AND COMPOUND TYPE  
 Compounds consumed were categorised according to their chemical structure 
and their baseline AChE values were analysed temporally. There were 4 categories as 
follows: Dimethyl compounds (12 patients), Diethyl compounds (10 patients), S-
Alkyl compounds (4 patients) and Unknown compound (4 patients). There was no 
significant difference in the AChE values between the 3 groups (p=0.757). However 
the apparent mean AChE was higher in the S-alkyl compounds. (Figure 12) 
 
Figure 12: Temporal profile of AChE level among the dimethyl (n = 12), diethyl (n = 10) and S-
alkyl (Profenofos) compounds (n = 4) 
 
AChE AND TIME TO PRESENTATION (Figure 13) 
 It is expected that the AChE levels would be higher in those who presented 
earlier compared to those who present late. Based on this, patients were divided into 2 
groups for analysis based on the lag time to presentation to CMC, Vellore: 
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2. Group B – Presented after 6 hours of consumption (11 patients) 
Patients who presented early had significantly higher baseline AChE value at 
presentation at 66.5% of normal compared to those who presented late at 22.2% of 
normal as shown in figure 13 (p value = 0.018). Moreover, their mean AChE values 
over time also remained higher than the late presenters and this difference tended 
towards significance up to day 3 (day 2 p=0.061 and day 3 p=0.053). 
 
Figure 13: Temporal profile of AChE among the early (n = 19) and late presenters (n = 11) 
 
AChE LEVEL AND PRIOR OXIME THERAPY (Figure 14) 
 Of the 30 patients, 20 had received treatment outside prior to arrival in CMC 
and 6 of these patients had documentation detailing the administration of prior 
pralidoxime (PAM) therapy elsewhere. None of the oxime doses were of adequate 
therapeutic dose based on WHO dosing schedule. The AChE in these two groups was 
also compared temporally. The mean AChE levels were lower in those who received 
prior oximes but this difference was not found to be significantly different (Figure 14). 
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> 6 hours 20.22% 20.41% 10.90% 16.99% 15.89% 18.53%
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Figure 14: Temporal profile of AChE among those who received PAM elsewhere (n = 6) 
compared to those who did not receive PAM (n = 24) 
 
REACTIVATION STATUS AND CLINICAL PROFILE OF OP 
POISONING  
 AChE (baseline) and AChE after addition of obidoxime to blood sample (post-
reactivation) were measured daily in OP poisoning patients for 5 days. In order to 
analyse the post-reactivation AChE values, the 30 OP poisoning patients were first 
sub-divided based on their baseline AChE level at presentation. Those patients with 
no significant inhibition, namely those whose baseline levels remained more than 30% 
throughout the course of their admission, were excluded from the analysis. This group 
consisted of 8 patients. The remaining 22 patients with inhibited baseline AChE levels 
(<30%) were further sub-divided based on the post-reactivation AChE at presentation.  
1. Group 1 – Reactivation present (13 patients) 
stat 12 hours day 2 day 3 day 4 day 5
PAM+ preoxime 40.26% 39.24% 32.28% 42.69% 25.68% 15.03%
PAM- preoxime 51.83% 51.87% 49.23% 50.93% 44.40% 48.92%
p=0.444 p=0.152 
p=0.368 
p=0.179 
p=0.145 
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- Included patients with AChE rising to above 30% at presentation after in vitro 
reactivation with oxime  
2. Group 2 – Reactivation absent (9 patients) 
- Included patients with no significant rise in AChE (AChE persistently < 30%) 
even after in vitro reactivation with oxime 
3. Group 3 – No inhibition of AChE (8 patients) 
- Baseline AChE > 30% throughout admission 
- This group was excluded from analysis regarding reactivation 
Table 6: Clinical characteristics of groups according to the reactivation status 
Clinical characteristics Group 1 (n=13) – 
Reactivation present 
Group 2 (n=9) – No 
reactivation 
p value 
Lag time to presentation to CMC – 
hours (±SD) 
      6.04(3.96)        10.94(8.06) 0.007 
Prior oxime therapy, n(%) 3(23.2%) 2(22%) 0.518 
Compounds 
Dimethyl, n(%) 
Diethyl, n(%) 
 
2(15.3%) 
6(46.1%) 
 
5(55.5%) 
0 
0.084 
 
 
Severity, n(%) 
mild 
moderate 
severe 
 
6(46.1%) 
4(30.7%) 
3(23.2%) 
 
0 
2(22.2%) 
7(77.7%) 
0.533 
 
 
Intermediate syndrome, n(%) 5(38.5%) 4(44.4%) 0.199 
 
IS duration – days (±SD) 7.0(4.7) 9.25(6.2) 0.905 
Mechanical Ventilation, n(%) 6(46.1%) 8(88.8%) 0.557 
 
Ventilation duration – days  7.37(4.79) 8.7(3.8) 0.755 
 
Atropine dose (mg) 139.2 480.5 0.209 
Atropine duration – days (±SD) 3.15 3.33 0.896 
Hospitalisation duration–days (±SD) 9.69 11.33 0.431 
Death, n(%) 0 3(33.3%)  
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 The group with reactivation had presented significantly earlier (mean of 6 ± 4 
hours) compared to the group without enzyme reactivation (mean of 11 ± 8 hours) 
(p=0.007). In the identified compounds, all the 6 diethyl compounds showed 
significant reactivation. In contrast, 5 out of 7 dimethyl compounds showed no 
reactivation. This difference tended towards statistical significance (p=0.084) Patients 
belonging to the group without reactivation required mechanical ventilation more 
frequently than the reactivation group of patients. Their mean duration of intermediate 
syndrome, ventilation and hospitalisation and mean atropine dose required were 
higher although these did not reach statistical significance. The need for mechanical 
ventilation and intermediate syndrome did not appear to be associated with the  
reactivability status. All 3 of the deaths in the study occurred in those patients with no 
reactivation with one death each occurring with monocrotophos and dimethoate (and 
one patient with unknown compound).  
Among the 13 patients who showed significant in-vitro post-reactivation level 
more than 30%, the mean reactivation AChE level was found to be 86.8% of normal. 
The mean magnitude of rise in AChE was 61.8% from baseline after addition of 
oxime to the sample. In these patients with significant reactivation, obidoxime was 
able to reactivate the enzyme to more than 30% for a mean duration of 2.35 days (S.D. 
± 1.7 days).  
 The mean post-reactivation AChE levels (expressed as % of normal) were 
plotted temporally for the ‗Reactivation‘ and ‗No reactivation‘ groups as described 
earlier (Figure 15). Among the group that showed significant reactivation, obidoxime 
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was able to reactivate AChE to a level of more than 30% up to day 3. There was 
significant difference in the mean post-reactivation AChE levels of groups 1 and 2 
until day 3. Those who did not have reactivation on day 1 continued to have non-
reactivable enzyme on subsequent days also. The number of patients with mean post- 
reactivation AChE levels > 30% of normal progressively reduced with 13 cases on 
day 1 with reactivability (>30%) compared to 9 cases on day 4 probably due to aging. 
 
Figure 15: Temporal profile of post-reactivation AChE in the 'Reactivation present' group (n = 
13) and the 'No reactivation' group (n = 9) 
 
REACTIVATION STATUS AND TIME TO PRESENTATION  
 The patients were divided into two groups based on the lag time (cut-off of 6 
hours) similar to the baseline AChE studies. In patients who presented early, 
obidoxime was able to reactivate the enzyme to more than 90% on the first 2 days and 
to more than 80% on the next 3 days. The baseline reactivation in early presenters (<6 
hours) was 96.82% of normal compared to 52.88% in late presenters (>6 hours) 
stat 12 hours day 2 day 3 day 4 day 5
Reactivation present 86.80% 71.41% 60.20% 62.60% 29.00% 33.85%
No reactivation 13.45% 15.68% 8.14% 9.63% 19.16% 16.04%
p=0.00 p=0.002 
p=0.001 p=0.007 
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(p=0.037) (Figure 16). However, it must be noted here that the baseline values were 
also higher for early presenters compared to later presenters. (Figure 16) 
 
Figure 16: Temporal profile of post-reactivation AChE among the early presenters (n = 19) and 
the late presenters (n = 11) 
 
REACTIVATION STATUS AND OP COMPOUND TYPE 
 OP compounds can be classified into dimethyl, diethyl and S-alkyl compounds 
depending on their chemical structure and these groups have different characteristics 
including ageing kinetics. The level of AChE after addition of oximes was analysed in 
the 2 major groups of dimethyl and diethyl compounds. The post-reactivation AChE 
values of the diethyl poisoning group were persistently higher than that of the 
dimethyl poisoning group but did not reach statistical significance. Day 1 and day 2 
post-reactivation levels were 101% and 95% respectively in the diethyl compound 
group compared to 65% and 69% in the dimethyl compound poisoning group (p value 
stat 12 hours day 2 day 3 day 4 day 5
Early presenters 96.82% 99.14% 94.56% 87.73% 85.01% 85.73%
Late presenters 52.88% 50.92% 31.14% 35.29% 21.06% 30.42%
p=0.037 p=0.111 
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= 0.16) despite lower baseline AChE levels in the diethyl group compared to the 
dimethyl group (Figure 18). 
 
Figure 17: Temporal profile of Baseline and Post-reactivation AChE among the dimethyl (n = 
12) and diethyl (n = 10) compounds  
 
The magnitude of reactivation of AChE with oximes (expressed as % of 
normal) was also significantly higher among the diethyl compounds compared to the 
dimethyl compounds and this difference was maintained till 4 days after consumption. 
Obidoxime was able to reactivate at least 30% of enzyme activity till 3 days after 
consumption for diethyl compounds. 
Figure 18 below depicts the magnitude of reactivation of AChE with 
obidoxime in 5 major OP compounds. Diethyl compounds, Triazophos and 
Chlorpyrifos, showed significant reactivation to >30% activity compared to the 
dimethyl and S-alkyl compounds.  
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Figure 18: Magnitude of rise in AChE after addition of obidoxime for the major OP compounds 
REACTIVATION STATUS AND INDIVIDUAL OP COMPOUNDS  
Table 7: Oxime induced AChE reactivation for different OP compounds 
Compound name Reactivation groups – Post-reactivation 
AChE level 
No inhibition of 
baseline AChE (n=8) 
>30% (n=13) <30% (n=9) 
Unknown 2 2 0 
Diethyl compounds 
Chlorpyrifos 2 0 0 
Quinalphos 1 0 1 
Triazophos 4 0 0 
Phorate 1 0 1 
Dimethyl compounds 
Monocrotophos 1 2 2 
Dimethoate 1 3 0 
Malathion 0 0 1 
Methylparathion 0 0 1 
Dichlorvos 0 0 1 
S-Alkyl compounds 
Profenofos 1 2 1 
p=0.025 
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In this study, there were a total of 10 different OP compounds distributed 
among the 30 patients. The distribution of these compounds among patient groups 
categorized based on reactivability is given in table 7. From this table, it was noted 
that the majority of the dimethyl (Monocrotophos and Dimethoate) and S-alkyl 
compounds (Propenofos) did not show reactivation compared to all the cases of 
diethyl compounds such as Triazophos and Chlorpyrifos which showed reactivation. 
 
INHIBITORY ACTIVITY OF PATIENT PLASMA 
 The patient‘s plasma inhibitory activity levels were expressed as the percentage 
of normal control AChE remaining after addition of patient‘s plasma in vitro. This 
was done by calculating the AChE of a control sample before and after the addition of 
patient‘s plasma. This indicates the ability of the patient‘s plasma to inhibit control 
RBC-AChE and is a functional indicator of the amount of the OP compound in the 
patient‘s plasma. This test was done only on those patient samples in which the BChE 
was less than 5000U/L. Out of the 22 patients on whom this study was done, only 11 
patients‘ plasma had the ability to inhibit control AChE to less than 90% of baseline at 
presentation. Among the remaining 11 patients, control AChE remained more than 
90% of baseline. The clinical characteristics of the two groups are described in table 8 
as follows: 
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Table 8: Clinical characteristics of compounds grouped according to inhibitory activity 
Clinical characteristics  Group I – AChE 
inhibited to <90% of 
baseline  
n=11 (as % of n) 
Group II – AChE 
remains >90% of 
baseline 
n=11 (as % of n) 
p value 
Lag time to presentation to CMC 
– hours (±SD) 
      9.45(7.89)        6.82(3.98) 0.65 
      Lag time < 6 hours, n(%)       5(45.45%)       6(54.55%) 0.68 
Prior oxime therapy, n(%) 3(27.27%) 2(18.18%) 0.95 
Compounds, n(%) 
dimethyl 
diethyl 
 
5(45.45%) 
5(45.45%) 
 
4(36.36%) 
3(27.27%) 
0.64 
 
 
Severity, n(%) 
mild 
moderate & severe 
 
1(9.1%) 
10(90.91%) 
 
 
6(54.55%) 
5(45.45%) 
0.025 
 
 
Intermediate syndrome, n(%) 5(45.45%) 4(36.36%) 0.39 
IS duration – days (±SD) 8.80(6.26) 7.0(4.1) 0.41 
 
Mechanical Ventilation, n(%) 13(72.2%) 4(33.3%) 0.67 
Ventilation duration – days 
(±SD) 
7.25(3.84) 9.20(5.1) 0.43 
 
 
Atropine dose (mg) 390.1 165.3 0.056 
Atropine duration – days 
(±SD) 
3.82(1.17) 2.73(1.19) 0.076 
 
 
Hospitalisation duration – days 
(±SD) 
11.82(8.33) 9.64(7.06) 0.365 
Death, n(%) 1(9.1%) 1(9.1%)  
 
Patients who had significant inhibitory activity at baseline (AChE after addition 
of patient plasma < 90%) had greater severity of poisoning (p=0.025) and higher 
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atropine dose (p=0.056). They were also associated with longer time to presentation 
and poorer outcomes in terms of need for mechanical ventilation, duration of atropine 
and duration of hospitalisation than the group without significant inhibitory activity 
though these difference did not reach statistical significance. The type of compound 
did not appear to have any relation to the inhibitory activity. Given the low level of 
inhibition of the control RBC AChE level, the significance of this assay is not clear. 
INHIBITORY ACTIVITY AND CORRELATION WITH SEVERITY 
 The inhibitory activity of patients‘ plasma was studied across the severity 
groups (Figure 19) and as from previous Table 8, samples of patients with moderate 
and severe poisoning showed a significantly greater mean inhibitory activity of 83.6% 
compared to 115% in mild poisoning (p=0.016) . The inhibitory activity of <90% 
persisted in moderate and severe poisoning till day 4 although the difference was not 
statistically different.  
 
Figure 19: Temporal profile of inhibitory activity according to severity. The mild group has 7 
patients and the moderate and severe group has 15 patients 
day 1 day 2 day 3 day 4 day 5
mild 115.00% 98.83% 95.83% 95.00% 93.00%
mod & severe 83.64% 88.33% 85.80% 87.00% 92.77%
p=0.016 
p=0.302 
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INHIBITORY ACTIVITY AND CORRELATION WITH 
INTERMEDIATE SYDROME AND MECHANICAL VENTILATION 
 Among the 22 patients, 9 developed intermediate syndrome and the ability of 
their plasma to inhibit AChE was persistently greater compared to the group which 
did not develop intermediate syndrome but reached statistical significance only on day 
2. Plasma of intermediate syndrome group of patients inhibited normal AChE to 83% 
and 79% on days 1 and 2 respectively compared to 101% (p=0.18) and 99% (p=0.02) 
for the group which did not have intermediate syndrome. (Figure 20) 
 13 of the 22 patients in this study required mechanical ventilation and their 
plasma inhibitory activity was persistently higher than the non-ventilated group but 
the difference was significant only on day 1 of poisoning. Control AChE was 
inhibited to a mean level of 82.7% of baseline by the plasma of the ventilated patients 
compared to 109.3% in the other group (p value = 0.028). (Figure 21) 
 
Figure 20: Temporal profile of plasma inhibitory activity of patients who developed intermediate 
syndrome (n = 9) compared to those who did not develop intermediate syndrome (n = 13) 
day 1 day 2 day 3 day 4 day 5
IS- 100.77% 99.00% 91.42% 92.27% 94.71%
IS+ 83.25% 78.88% 85.00% 86.78% 91.33%
p=0.185 p=0.016 p=0.382 
p=0.175 
p=0.681 
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Figure 21: Temporal profile of plasma inhibitory activity of patients who required mechanical 
ventilation (n = 13) compared to those who did not require ventilation (n = 9) 
 
INHIBITORY ACTIVITY AND TIME TO PRESENTATION 
 Out of 22 patients, 11 presented within 6 hours. Among these patients, their 
plasma, on an average had the capacity to inhibit control AChE to 84% compared to 
103% for the late presentation group (p value = 0.314). However, there was no 
significant difference in the inhibitory activity of the two groups.  
 
Figure 22: Temporal profile of plasma inhibitory activity among the early presenters (n = 11) 
and late presenters (n = 11) 
day 1 day 2 day 3 day 4 day 5
MV- 109.33% 96.25% 93.25% 93.56% 96.50%
MV+ 82.67% 88.31% 85.85% 86.73% 91.58%
p=0.028 
p=0.374 p=0.268 p=0.552 
p=0.446 
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RESULTS – (B) STUDY OF POISONING PROFILE USING 
THE POISON DATABASE 
 The results from the analysis of the poison database 2009-2014 was as follows: 
DEMOGRAPHIC CHARACTERISTICS 
 A total of 2323 patients who presented with poisoning between July 2009 to 
June 2014 were evaluated. The mean age (±SD) was 30.47(12.23) with a range of 14 - 
90 years. Almost half the population belonged to the young adult age group of 20-29 
years. 81% of the patients were less than 40 years of age. (Figure 23) 
 
Figure 23: Number of poisonings according to age-groups 
 Among the patients with pesticide poisoning, this trend was maintained and 
about 75% of the population was below 36 years of age as depicted below in figure 
27. (Figure 24) 
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Figure 24: Pesticide poisoning according to age-group 
 There was a slight male predominance (52%) among all poisoning cases which 
was more prominent in pesticide poisoning (64.5%). However, there was a female 
predominance (66%) in the 635 cases of drug overdose. (Figure 25) 
 
Figure 25: Sex distribution for all poisonings, pesticide poisoning and drug overdose 
 Most of the patients who presented to our centre were from Tamil Nadu (82.9) 
with most patients belonging to Vellore(62.9% of all poisoning cases) and 
Thiruvannamalai(16.9%) districts. 16.2% of all the poisoning patients were from the 
neighbouring state of Andhra Pradesh predominantly belonging to the districts of 
Chittoor and Kadapa. 
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 Housewives accounted for 27% of poisonings of all causes with labourers 
being the largest occupation group accounting for one-quarter of the cases of 
poisoning. (Figure 26) In pesticide poisoning, farmers (17%) and labourers (32%) 
accounted for nearly half the cases while in plant poisoning, labourers and housewives 
were the predominant groups.  Housewives (39%) and students (20%) constituted 
most of the cases of drug overdoses. The figure 27 highlights that pesticide poisoning 
followed by drug overdose is the most common method of poisoning among 
labourers, farmers and students and among housewives‘ the common method is drug 
overdose followed by pesticide poisoning.  
 
Figure 26: Compound used and occupation 
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Figure 27: Occupation and class of poisoning 
 
CLASS OF POISONS AND TIME TREND OF POISONING  
Of the 2323 cases of poisoning, 28 cases were due to accidental poison 
ingestion with all the remaining cases presenting with deliberate self-harm. There had 
been no cases of homicide admitted in our centre during this period with poisoning. 
88% consumed only a single compound with the rest consuming 2 or more 
compounds which were most often combination of different classes of drugs or mixed 
classes of poisons. 1178 among the 2323 cases were attributed to pesticide poisoning 
accounting for 50.7% of all poisonings. Drugs (27.3%) followed by plants (9.7%) 
were the next most common agents used for poisoning. Rodenticides were used in 
4.4% of all poisonings and corrosives including hair dyes in 4%. (Figure 28) 
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Figure 28: Numbers of poisoning of different classes 
 
The overall percentages of the classes of compounds used for poisoning have 
remained stable over the years as evidenced in figure 29. Pesticides have accounted 
for about half the cases of poisoning every year between July 2009 to June 2014. 
Drugs have remained the second most common method of poisoning with percentages 
being slightly higher in 2012-13 and 2013-14 (28.6% and 27.1% respectively) 
compared to 2011-12(22.70%). The share of plant poisonings among all causes of 
poisoning has remained stable in the time period of the study ranging from 8.8% to 
10.9%.  
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Figure 29: Proportion of different classes of compounds in each year 
 Analysis of the time trend of the number of poisonings in 2009-14 shows that 
there has been a marked decline in the overall numbers of all poisoning cases 
presenting to our institution which has been represented graphically in Figure 30. 
While there were 570 and 598 poisoning cases in 2009-10 and 2010-11 respectively, 
there were only 374 and 387 cases in 2012-13 and 2013-14 respectively. Each of the 
individual compound poisonings including pesticide, drug, plant and corrosive 
poisonings showed a marked decline over the 5 year time frame except for rodenticide 
poisoning, the numbers of which remained stationary. While the number of pesticide 
poisoning patients dropped from 274 in 2009-10 to 198 in 2013-14 (proportional fall 
of 27.7%), the numbers in the drug overdose group fell from 181 to 105 in this same 
period (proportional fall 42%). While the number of plant poisoning cases peaked at 
61 in 2010-11, there has been a decline to 37 cases in the last recorded time period of 
2013-14 (proportional fall of 39.3%). Further it is also clear that the decline of all 
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poisonings occurred in the period of 2011-12 compared to the period before this 
(2009-2011) (proportional fall 33.7%). In the period of 2012-2014, the number of 
poisonings and the proportion of different classes remained stationary. Therefore it is 
clear that there was a change in the admission pattern of poisonings during 2011-12 
which affected the majority of poison compounds and this change has been sustained 
after that. 
 
Figure 30: Year-wise number of poisonings of each class 
It appears from the above graph that there was a sharp decline in all poisons 
between 2010-11 and 2011-12. Since that time the number of each kind of poisoning 
has remained stationary. The number of poisonings during these years and the 
proportional decline of poisoning in this time period (expressed as a percentage of the 
2010-11 numbers) is summarised below in table 9. 
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pesticide 274 294 216 189 198
rodenticide 18 28 19 16 21
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Table 9: Proportional decline in the number of different classes of poisonings in 2011-12 
compared to 2010-11 
Compound class Number of cases in 
2010-11  
 
Number of cases in 
2011-12  
 
Proportional decline (as 
% of 2010-11) between 
2010-11 and 2011-12 
Overall 598 387 35.28% 
Pesticide 294 216 26.53% 
Rodenticide 28 19 32.14% 
Plant 61 42 31.15% 
Drug 154 88 42.86% 
Corrosive  32 9 71.88% 
 
PESTICIDE POISONING 
 Of the 1178 cases of pesticide poisoning, organophosphorus compounds were 
used in 50% of cases of which organophosphates were combined with pyrethroids in 
8% of cases. Pyrethroids were associated with 23% of all pesticide poisonings. 
Organochlorines and Carbamates were the causative agents in 5% and 2% of patients 
respectively. In a quarter of the patients, the pesticide compound was not known. The 
pesticides were also classified according to the WHO class of toxicity and class II 
compounds which are under the moderately hazardous agents were the most common 
agents used, accounting for 42.6% of pesticide poisonings. The extremely and highly 
hazardous compounds of class Ia and Ib constituted 26.5% of pesticide poisonings. 
Among the individual compounds, chlorpyrifos and monocrotophos were the most 
common compounds used with 104 and 99 cases respectively. The class Ia 
compounds of phorate, methylparathion and parathion accounted for 60, 62 and 15 
cases respectively. 
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Figure 31: Pesticide poisoning proportion according to category and WHO class of toxicity 
 The temporal profile of pesticide poisoning was analysed according to the 
WHO class of toxicity of pesticide poisoning and the category of pesticides. There 
was a drop in overall numbers in all categories as well as the relative percentages of 
different categories. Class II compounds which constituted 38.3% of pesticide 
poisonings in 2009-10 accounted for 44.8% in 2013-14 constituting a 6% rise in 
proportions although there was a drop in absolute numbers from 104 to 87 cases. The 
class I compounds remained as the causative agents in about 30% of cases. When 
analysed by category, there was a rise in proportions between 2009-10 and 2013-14 of 
organophosphorus compounds (55.7% to 64.7%). The combined formulations of OP 
and pyrethroid which constituted 7.2% of pesticide poisonings in 2009-10 peaked to 
16.4% in 2012-13 and again declined to 8.7% in 2013-14. There was a marked decline 
of proportion of organochlorine poisoning (11.86% in 2009-10 to 2.0% in 2013-14) 
and pure pyrethroid poisoning (21.1% in 2009-10 to 15.0% in 2012-13). The newer 
pesticides which could not be classified into any of these categories were less than 1% 
in all the years. 
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Figure 32: Temporal profile of pesticide poisoning according to category and WHO class of 
toxicity 
 
ENDOSULFAN 
 Out of the 58 cases of organochlorine poisoning, there were 39 cases of the 
highly fatal endosulfan poison. There was a sharp decline in the number of endosulfan 
poisoning cases during the period of the study with 30 cases up to June 2011 and 9 
cases thereafter. This decline was simultaneous to the national ban on Endosulfan in 
2011. There were no cases of endosulfan poisoning after June 2013. The graph also 
shows that the mortality due to Endosulfan which was 29.4% was in 2009-2010 was 
completely eliminated which shows the efficacy of the ban and the impact of pesticide 
restriction on poisoning mortality. (Figure 33) 
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Figure 33: Temporal profile of endosulfan poisoning - number of cases and deaths due to 
endosulfan 
  
RODENTICIDE POISONING 
 There were 102 cases of rodenticide poisoning in the 5 years of study with the 
compound not being known in 43% of cases. Zinc phosphide was the most common 
rodenticide followed by yellow phosphorous, coumarins and aluminium phosphide 
with percentages as depicted below (Figure 34) 
 
Figure 34: Proportions of different rodenticide compounds used 
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PLANT POISONING 
 Of the 226 cases of plant poisoning, there were 120 and 102 cases of yellow 
oleander and Oduvanthalai poisoning respectively. There was a significant fall in the 
number of plant poisonings with 111 cases in the first two years of study compared to 
73 cases in the last two years of the study period. In comparison to 50 and 49 cases of 
oleander and oduvathalai poisoning in the 2009-11, there were 34 and 29 cases 
respectively in 2012-14. (Figure 35) 
 
Figure 35: Proportions of different plant poisons used and the temporal profile of the number of 
plant (overall), oleander and oduvanthalai poisoning 
 
DRUG OVERDOSE 
 There were 635 patients presenting with drug overdoses to our hospital during 
the study period of whom, 135 had consumed 2 or more different classes of drugs. In 
69 patients, the offending drug was not known. The most common drugs used were 
benzodiazepines with 152 cases due to this class (constituting 24% of the drug 
overdose cases) with barbiturates being used in only 29 cases (4.5%). Other 
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antiepileptics were used in 61 cases (9.5%). Paracetamol and NSAIDs were used in 96 
cases and antihistaminics in 63. Among the antipsychotics, atypical antipsychotics 
were more commonly used in 70 cases (11%) in comparison to 11 (1.7%) for typical 
antipsychotics. Other central nervous system agents such as antidepressants were the 
causative agents in 75 cases (11.8%). Poisoning due to all the major classes of drugs 
were on a downward trend similar to the trends of overall poisoning with no increase 
in any specific group. Other drugs had small numbers accounting for less than 20 
cases. 
CORROSIVES 
 There were 92 cases of corrosive poisoning during the study period with super 
vasmol hair dye being the most common agent used in 28% of cases. (Figure 36) 
There was a fall in overall numbers of corrosive poisoning from 65 cases in the first 2 
years of the study period to 20 cases in the last 2 years. Phenol or Lysol toilet cleaners 
were used in 24% of cases and hydrochloric acid in 22%. There was a relative fall in 
the number of cases of super vasmol poisoning with only 7 cases in the last 2 years of 
the study period compared to 16 cases in the first 2 years. 
 
Figure 36: Proportions of different corrosives used, %(n) 
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OUTCOME OF POISONING AND THE TEMPORAL PROFILE 
 907 out of 2323 patients with poisoning (39%) did not require admission and 
were discharged from casualty. Of the remaining patients, 733 (31.6%) required 
treatment in Intensive Care Unit (ICU). Patients with drug overdoses were more likely 
to get discharged from casualty with 66.1% not requiring admission to ward. 
Although the percentages of patients discharged from casualty was high with 
rodenticide and corrosive poisoning constituting 58% and 44% respectively, this may 
have been related to the greater number of patients discharged against medical advice. 
The proportion of patients requiring ICU care for individual poisons was as follows: 
Pesticide (47.2%), Drug (9.8%), Plant (13.7%), Corrosive (14.6%) and Rodenticide 
(29.8%). (Figure 37) 
 
Figure 37: Admission status for different classes of poisons 
pesticide rodenticide plant drug corrosive
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 103 out of 2323 patients died resulting in death rate 4.4%. 116 (5%) patients 
were discharged against medical advice.  Mortality rate was highest for plant 
poisoning with 9.7% of patients succumbing to their illness. Death rate for pesticide 
poisoning was 5.1%. The rate of overall poor outcome which includes both death and 
Discharge Against Medical Advice (DAMA) was highest for corrosive poisoning at 
21.2% followed by plant poisoning at 15.9%. Rodenticide poisoning was associated 
with poor outcome in 14.7% of cases. Drug overdose resulted in death in 0.9% of 
cases. (Figure 38) 
 
Figure 38: Outcomes of different classes of poisons 
  
pesticide rodenticide plant drug corrosive
DAMA 4.4 10.8 6.2 3.1 13.8
Dead 5.1 3.9 9.7 0.9 7.4
Alive 90.4 85.3 84.1 95.9 78.7
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On analysing the temporal profile of mortality rates, the rates of poor outcome 
in pesticide poisoning was on a downward trend and reduced from 15% in 2009-10 to 
4.5% in 2013-14. There was an increase in the poor outcome rates in rodenticide 
poisoning rising from 11.2% to 23.8% during the same periods. Although plant 
poisoning was associated with poor outcome in 24% of cases in 2009-10, it was stable 
in the next 4 years at 13.5%. (Figure 39) 
 
Figure 39: Temporal profile of poor outcome (as % of poisoning) for different classes of poisons 
 
PESTICIDE POISONING 
  Among the pesticide poisons, 65% and 60% of organophosphorus and 
organochlorine compound poisoning required ICU care. Pyrethroid poisoning without 
combination with OP compound was associated with ICU care in 15% of cases and 
64% were discharged from casualty. In contrast, Pyrethroid combinations with OP 
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required ICU admission in 50% of cases. Class Ia and Ib compounds based on the 
WHO class of pesticide toxicity required ICU admission in 65% and 68% of cases 
respectively compared to 43% and 44% for class II and class III compounds 
respectively. Rates of discharge from casualty were also higher in class II and class II 
compounds. (Figure 40) 
 
Figure 40: Admission status for different categories of pesticide poisons and according to WHO 
class of toxicity 
  
The mortality rate was highest for organochlorines among the pesticides at 
15.5% with endosulfan poisoning being associated with death in 20.5% of cases. 
Organophosphorus compounds which constitute the majority of pesticide poisonings 
had a mortality rate of 5.2% with overall poor outcome in 8.9% of cases. While pure 
pyrethroid poisoning was not associated with any deaths, formulations of pyrethroid 
combined with organophosphates had a death rate of 9.3%. On analysing the mortality 
rates among the different pesticides according to their WHO class of toxicity, it was 
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found that the highest mortality rate was for the class II compounds at 6% with class 
Ia and Ib compounds having rates of 5% and 3.3% respectively. However, the overall 
poor outcome was almost comparable between the three classes at 7.9%, 9.3% and 
8.6% respectively for class Ia, Ib and II compounds. Class III compounds were not 
associated with any deaths. (Figure 41) 
 
Figure 41: Outcome for different categories of pesticide poisons and according to WHO class of 
toxicity 
  
Among the individual OP compounds, the highest mortality rate was for 
Chlorpyrifos at 7.6% but the poor outcomes were greater with monocrotophos at 
11.1% as depicted below in Figure 42. The rates of poor outcome for individual OP 
compounds (with more than 50 cases during the study period) were as follows: 
Chlorpyrifos (8.6%), Methylparathion (8.3%), Monocrotophos (11.1%), Phorate 
(8.3%), Profenofos (7.7%), and Triazophos (8.6%).  
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6 out of the 8 deaths in the chlorpyrifos group occurred in those who had taken 
a combined formulation with cypermethrin. All 3 deaths in the triazophos group 
occurred in the combined formulations with deltamethrin. 
 
Figure 42: Outcome of individual OP compounds 
 
RODENTICIDE POISONING 
 Among the rodenticide poisons, the worst outcomes were with yellow 
phosphorous with death or DAMA occurring in 44.4% of the patients compared to 
16.7% and 15.8% in the aluminium phosphide and zinc phosphide groups 
respectively. Coumarin derivatives or super-warfarins were associated with good 
outcomes in all cases. (Figure 43) 
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Figure 43: Outcomes of different classes of rodenticide poisoning 
 
PLANT POISONING 
 Overall rate of poor outcome in plant poisoning was 15.9% with death in 9.7% 
of cases. However, death rate was significantly higher in the Oduvanthalai group at 
19.2% compared to 1.6% for oleander poisoning. Poor outcome in Oduvanthalai 
poisoning was 27.9% compared to 5.7% for oleander poisoning. (Figure 44) 
 
Figure 44: Outcomes of plant poisons - oleander and oduvanthalai 
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DRUG OVERDOSE 
 Drug overdose was associated with discharge from casualty itself in 66.1% of 
cases. Among the individual drugs, ICU admission rates were highest for barbiturates 
(52.9%) followed by antidepressants (32%). (Figure 45) There were 6 deaths in the 
drug overdose group with one each due to iron and chromium poisoning. Barbiturates 
were associated with 1, other antiepileptics with 3 and atypical antipsychotics with 2 
deaths. 
 
Figure 45: Admission status and outcomes of different groups of drugs 
 
CORROSIVE POISONING 
 Out of the 7 deaths in the corrosive poisoning group, 2 were due to super 
vasmol poisoning and 2 were due to toilet cleaning hydrochloric acid. Both the deaths 
in the super vasmol group occurred in the 2009-10 time period. The super vasmol 
mortality fell from 11.8% in the first two years of the study to 0 in last two years of 
the study. 73.1% of super vasmol poisoning patients required ICU admission.  
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DISCUSSION – (A) TRIPLE CHOLINESTERASE TEST IN 
ORGANOPHOSPHORUS POISONING 
 The main findings of this study to evaluate the triple cholinesterase test in OP 
poisoning were as follows: 
TEMPORAL PROFILE OF AChE 
 RBC-AChE levels were shown to have correlation with clinical presentation 
and outcomes. Those with severely inhibited AChE at baseline were more likely to 
have had a late presentation with more severe manifestations. They were also more 
likely to require mechanical ventilation and develop intermediate syndrome with 
longer durations of ventilation and intermediate syndrome. Their atropine requirement 
was also found to be higher. This reflects the utility of RBC-AChE as a good index of 
severity and prognostic marker in view of its good correlation to clinical markers of 
severity and complications. This finding supports existing literature on RBC-AChE 
which suggests that it is a better marker for determining clinical severity than 
BChE.(82–84) 
 
REACTIVATION STUDIES 
DEMONSTRATION OF REACTIVATION 
The literature on the efficacy of oximes has been controversial so far. Despite 
theoretical benefit, definite efficacy has not been proven in clinical settings. This 
study has biochemically demonstrated that oximes can reactivate the inhibited AChE 
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enzyme in-vitro. Among the 22 patients with inhibited AChE levels, obidoxime was 
able to reactivate the enzyme in 13 patients (60%) of the patients.  
CLINICAL CORRELATES 
 Several recent studies have postulated that there may be certain clinical sub-
groups in which oxime therapy may be effective.(42,69) The first question that this 
study sought to answer was to identify the clinical characteristics of the group that 
may benefit from oxime therapy. The study shows that the patients who 
demonstrate in-vitro oxime reactivation of AChE are: (1) those who present 
within 6 hours (up to 10 hours) after consumption of the compound and (2) those 
with Diethyl OP compound poisoning. 
Patients who present later have progression ageing of enzyme with time, 
thereby reducing its reactivation potential.(2,4)  This study particularly found 
significance in the in vitro reactivation of AChE in diethyl compound poisoning with 
triazophos and chlorpyrifos. This is explained by the differences in ageing kinetics 
between diethyl and dimethyl compounds as their ageing half-lives are 31 hours and 
3.7 hours respectively. This means that at the end of 5 days, the enzyme activity 
would be reduced to 6.3% among the diethyl compounds whereas the same level 
would be reached within 16 hours for dimethyl compounds. The dose of oximes 
required to reactivate the enzyme has also been found to be different between the two 
groups.(2,46) There were a few patients with dimethyl compound poisoning also in 
the reactivated group. Patients with dimethyl poisoning with significant reactivation 
could be identified by using this triple cholinesterase test. The second question 
that this study sought to answer was the duration for which the AChE could be 
90 
 
reactivated. Among the patients with significant reactivation on day 1, oximes 
could reactivate the enzyme for an average of 2.3 days and in some patients, up 
to 4 days. 
IMPLICATIONS OF THE STUDY 
 There was a lack of clinical benefit from oxime therapy in several previous 
studies which has been attributed to the uneven distribution of baseline characteristics 
including compound type, quantity and variation in time to presentation.(74) Based on 
the recommendation of Eddleston et al to identify sub-groups who would benefit from 
oxime therapy, the triple cholinesterase test was evolved. It has been advised to 
administer oximes based on the results of this test.(7,8) The present study is an ex-
vivo study that attempts to correlate the laboratory results of oxime-induced enzyme 
reactivation with the clinical characteristics of the patients. It was found that the 
patients with significant reactivation and therefore, most likely to benefit from oximes 
are those who present early after OP poisoning with a diethyl compound.  
The triple cholinesterase test can be used to identify patients with significant 
reactivation of AChE at baseline and serially. These patients would be targets for 
oxime therapy in clinical settings. The oxime dose can be further titrated to achieve 
complete reactivation of the enzyme which can be monitored using this test. Oxime 
should also be continued in-vivo until there is no further significant reactivation of the 
enzyme using this test. The ability to identify patients who could potentially benefit 
from oxime therapy through a laboratory test, paves the way for a future tightly 
controlled clinical trial in which oximes will be administered based on the results of 
this test with further dosing guided by serial monitoring of cholinesterase status.  
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INHIBITORY ACTIVITY BIOASSAY 
 The inhibitory activity bioassay is a functional marker of the OP compound in 
the patient‘s sample. The degree of inhibition found in this study was lesser than that 
found in other studies using this assay.(7,8,88) In our study, it was found that those 
patients whose plasma inhibited the control AChE to < 90% were associated with 
poorer clinical outcomes in terms of severity at presentation, need for mechanical 
ventilation, duration of intermediate syndrome and hospitalisation and the dose and 
duration of atropine required. The significance of this 10% level of inhibition in the 
severely poisoned patients is not known and this test requires greater critical 
examination both in the laboratory and in clinical studies. 
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DISCUSSION – (B) STUDY OF POISONING PROFILE USING 
THE POISON DATABASE 
 Poisoning, especially pesticide poisoning is a common mode of suicide in 
India.(11) In view of the under-reporting of poisoning cases in India, the WHO 
advocated for the establishment of poison information or control centres across the 
country.(17,32) In the department of Medicine in CMC, Vellore, we have a poisoning 
documentation system in which a dedicated staff prospectively collects information of 
poisoning cases using a standardised form. This study was done on the poison 
database which had been compiled between July 2009 and June 2014 over a period of 
five years. 
DEMOGRAPHIC CHARACTERISTICS  
 There was an overall slight male predominance for all poisonings. But males 
were more likely to consume pesticide compounds whereas women were more likely 
to used drugs for poisoning. As in previous studies(13), most of the cases of poisoning 
occurred in the young working population with over 75% of all poisonings, including 
the pesticide poisonings, occurring in persons below the age of 40. Most of the 
patients were farmers or labourers with pesticides being the most commonly used 
poison. Housewives and students were another large population group accounting for 
the poisoning cases and these groups were more likely to consume drugs or pesticides. 
The demographic characteristics are useful to identify the target population for 
preventive measures for poisoning and suicide which should include young workers 
from the farming community, students and housewives. 
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COMPOUNDS USED FOR POISONING AND THEIR TIME-TRENDS 
 Most studies in India have found pesticides, especially organophosphate 
compounds, to be the most commonly used agents for poisoning.(1,18) This was 
reflected in our study as well with half the cases being due to pesticide poisoning. 
Drugs accounted for a quarter of the cases with plant poisoning in one in every tenth 
person presenting with poisoning. What makes these pesticides the most popular 
compounds for poisoning is their easy availability and access, especially in a farming 
community. 
DECLINE IN POISONING CASES AND POSSIBLE REASONS 
 It was noted from this study that there was a sharp decline in the overall 
numbers of all poisonings from 2010-11 to 2011-12 and the numbers remained stable 
thereafter.  As this fall occurred across all classes of poisoning with no change in the 
proportion of different compound classes, it does not appear to be a reflection of a 
change in epidemiology of attempted suicide (Deliberate self-harm or DSH) and 
poisonings at a community level. There could be several reasons for this decrease in 
numbers of all poisoning cases as detailed below: 
1. There may have been a fall in the DSH rates among the community during this time 
period. This is unlikely as there has been no change in the social circumstance and no 
apparent similar national or regional trend that has been documented. 
2. There could be change in the access to specific compounds that would influence 
compound-specific DSH rates. This decline has affected all compounds and therefore 
unlikely to be due to change in access to poisons.  
94 
 
3. The apparent decline may represent a change in the referral pattern at the district level. 
The ICU facilities in the Government Medical College in the district have been upgraded 
and there has been strengthening of taluk hospitals which are handling poisoning cases. 
There are other private hospitals with ICUs in the district. The upgrading of the tertiary 
and secondary level hospitals particularly in the government health system and also in the 
private health system may have led to the decrease in the poisoning referrals to this centre 
which for long had been the only centre with ICU facilities for poisoning management in 
the district. Hence to improve poisoning care at the district level, we need to focus across 
hospitals to improve guidelines, training and inter-hospital referral.   
COMPOUNDS WITH AN INCREASING TREND 
 Although there was a downward trend in the numbers of all poisonings, there 
were certain classes of compounds with an increasing trend. This was especially seen 
among the combined formulations of OP with pyrethroids which accounted for 8% of 
pesticide poisonings although there was a decline in the proportions of pure 
pyrethroids. This suggests that there are increasing marketing, sales and use of 
OP/pyrethroid combination formulations which is leading to the rising trend. The 
rising trend and higher mortality suggests the need for restriction of this class of 
compounds. The relative fall in numbers was less among the pesticides than other 
classes of compounds. Chlorpyrifos and monocrotophos were the most popular OPs 
and the numbers of the individual OP compounds remained stable post-2011.   
COMPOUNDS WITH A DECREASING TREND 
 The decline in numbers was more prominent among certain classes of 
compounds. Pure pyrethroids, which had good outcomes, showed a drop in 
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proportions compared to the OP and pyrethroid combination compounds which are 
associated with poor prognosis. Organochlorines which have a high mortality rate 
were also on progressive downward trend. This may be due to the fall in numbers of 
endosulfan poisoning. There was also a sharper drop in proportions of all the 
corrosives including super vasmol hair dye.  
EFFECT OF ENDOSULFAN RESTRICTION? 
 A study done in Sri Lanka by Eddleston et al showed that there was a fall in 
poisoning mortality without fall in numbers after restriction of the most toxic 
pesticides including endosulfan and the WHO class I toxicity compounds.(24)  In 
India, the Supreme court passed an order banning endosulfan in May 2011.(90) 
Although the ban could not be strictly implemented, measures to restrict endosulfan 
use were instituted and it was planned to phase out endosulfan by 2017 in the country. 
In our study, it was found that endosulfan, which had a high mortality rate of 20%, 
was on a sharp decreasing trend and that there were no cases of endosulfan poisoning 
after June 2013. This could reflect the effectiveness of the restriction measures and 
strengthens the argument that restriction or ban of the highly toxic compounds, 
including WHO class Ia and Ib compounds, could eventually reduce poisoning 
mortality. In this study, there were more than 500 cases of OP poisoning, 70% of 
which were due to the Class I and Class II OP compounds. Nearly all the 25 deaths 
due to OP compounds could have been prevented had these compounds been 
restricted as has been done in Sri Lanka. 
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OUTCOMES OF POISONING 
 Although poisoning mortality, including mortality due to pesticides, in this 
study was 5% which was lower than that found in other studies in India, there were 
certain compounds associated with poorer outcome than others.(18) While OP 
compounds had 5% mortality rate and pure pyrethroids were not associated with any 
deaths, the combined formulations of OP and pyrethroids had a much higher mortality 
rate at 9.3%. This could be due to the synergistic effect of the two classes of 
compounds or it could reflect the effect of the higher dose of the OP compound in 
these formulations. This finding of increased toxicity in this group is similar to 
another study done in the same institution.(91) The ICU admission rates and mortality 
rates were uniformly high in WHO class Ia, Ib and II compounds reflecting their 
highly toxic nature compared to the WHO class III compounds. These findings should 
be taken note of to implement further preventive and restrictive measures.  
 Super vasmol poisoning was associated with 2 deaths, both of which occurred 
in the first year of the study period. The reduction in mortality rates following this 
period may be related to the reduction in the concentration of the toxic component, 
PPD (ParaPhenylene Diamine) in the commercial form of this hair dye.(92,93) In 
view of high mortality due to Super vasmol poisoning, our institution had worked 
with the company to reduce the PPD concentration. This reduction may have led to 
the reduced mortality. This finding also emphasises the importance of clinicians 
working with chemical companies towards reformulation to reduce toxicity. 
 Other compound classes associated with poor outcomes were the corrosives 
and rodenticides as well as oduvanthalai. These compounds not only had high 
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mortality rates, they also had high rates of discharge against medical advice which 
may be a reflection of the poor prognosis of these patients. While these poisonings are 
difficult to treatment, the analysis suggest that they should be the target for focussed 
improvement in management through training, guidelines and research into specific 
treatment strategies to improve outcomes.  
PREVENTIVE MEASURES  
 It appears from this study that the implementation of restriction on endosulfan 
helped in reducing the numbers of this toxic compound. It may be prudent to consider 
implementation of similar measures for the other highly toxic pesticides of WHO class 
I and II to curb their use and reduce poisoning mortality. The specific characteristics 
of the combined formulations of OP with pyrethroids also need to be investigated in 
view of high mortality rates. 
 The study showed the benefit of a prospective data base in monitoring trends of 
poisoning which shows the impact of change in referral patterns, pesticide restriction 
(endosulfan), compound reformulation (Super vasmol), marketing of new 
formulations (OP with pyrethroid combined formulations) and identifying high risk 
groups for improvement in management (corrosives, oduvanthalai and rodenticides). 
Such data need to be fed back to the Government to influence pesticide policies. It 
also shows the need for establishment of Poison centres in each medical college. Audit 
of outcomes of poisonings can identify priorities for improvement in poison 
management through clinical guidelines and training and also research priorities for 
strategies to reduce mortality and poor outcome. 
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CONCLUSION 
 Organophosphorus poisoning is a major problem in South India. Oximes, 
which are the specific antidotes for OP poisoning, have not shown clear benefit in 
clinical studies and recommendations regarding their use is controversial. This study 
has shown that oximes can induce ex-vivo reactivation of the inhibited 
acetylcholinesterase enzyme to adequate levels in at least 60% of patients. The 
patients in whom the enzyme was reactivated with oximes were those who presented 
early to the hospital, within 6 hours (± 4 hours) and those who had consumed the 
diethyl OP compounds, such as triazophos and chlorpyrifos. Among the patients with 
reactivation, oximes continued to reactivate the enzyme significantly for an average of 
2.35 days (± 1.7 days).  
 It has been shown from this study that this test can be applied in a clinical 
setting to identify patients with good reactivation at admission. Therefore this test has 
potential use to plan administration of oximes in these patients who are most likely to 
benefit from oxime therapy. This test can also be used temporally on serial samples to 
guide oxime dose and duration of administration. This test could be used for a future 
controlled clinical trial to test the efficacy of selective administration of oximes in 
patients who demonstrate ex-vivo oxime reactivation. 
 Although serum from patients with severe poisoning had greater inhibitory 
activity, the role of the inhibitory assay as a functional indicator of the presence of the 
OP compound in the plasma is not yet clear.  
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 The second part of the study which dealt with the profile of poisonings has 
shown the benefit of maintaining a poison database in order to identify the toxic risks 
in the community. Certain time-trends have become apparent from this study 
including the sharp decline in all poisonings after 2011 which may be due to a change 
in the referral pattern to this institution. The efficacy of restriction measures was 
reflected in the fall in numbers and mortality of the organochlorines, especially 
endosulfan.  Further compounds have been identified for restriction including the class 
I and II pesticides and OP/pyrethroid combinations in view of their high rates of poor 
outcomes. The effect of reformulation has been demonstrated by the fall in mortality 
due to super vasmol and increased mortality with OP and pyrethroid combined 
formulations. High-risk poisoning groups with poor outcomes have been identified 
which include corrosives, rodenticides (mainly yellow phosphorus) and Oduvanthalai. 
Training guidelines and improvement in management strategies need to be put in 
place to improve outcomes in these poisonings. The results from this database can 
used to assist in framing public health policy regarding pesticide use and restriction. 
There is need to establish a poison control centre in each medical college to monitor 
the poisoning risks at a regional level.  
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LIMITATIONS 
(A) TRIPLE CHOLINESTERASE TEST IN ORGANOPHOSPHORUS POISONING 
1. The sample size was small as this was a pilot study and even among these 
patients, there were a few patients who did not show significant baseline 
inhibition of AChE despite toxidrome features being present.  
2. The inhibitory bioassay did not show very low levels and most values were 
above 80%. This may be related to the dilutions used. The numbers tested was 
also small. Further studies would be required to determine the significance of 
this test. 
3. HPLC measurement of OP compounds in the patient‘s blood could not be done 
to support the clinical and laboratory studies.  
4. This was a clinico-laboratory based study and only shows the reactivation of 
the AChE enzyme by obidoxime ex-vivo on blood samples taken from the 
patient. Further controlled clinical trials are required where the triple 
cholinesterase test is used to guide oxime therapy in selected cases of OP 
poisoning.  
 (B) STUDY OF POISONING PROFILE USING THE POISON DATABASE 
 One limitation from this study was the large number of unknown compounds 
which could not be analysed. This was a limited retrospective study to determine the 
changing profile and outcomes of poisoning and further detailed analysis including 
clinical characteristics for each different poison can be derived from the poisoning 
database for later studies. 
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ANNEXURES 
 
ANNEXURE 1 – PATIENT INFORMATION SHEET 
Study Title: A STUDY TO EVALUATE THE USE OF TRIPLE 
CHOLINESTERASE TEST IN PATIENTS WITH ORGANOPHOSPHORUS 
POISONING 
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
 Your family member has been admitted with pesticide poisoning due to 
Organophosphorus insecticides. The treatment of this condition consists of supportive 
measures such as drugs to neutralise the effect of poison, close monitoring and supports for 
respiration where required. These poisons act by blocking proteins called enzymes in the 
brain and nerves causing paralysis and breathing difficulty. The name of this protein that is 
blocked is called cholinesterase. There are a class of drugs called oximes that can reverse the 
blocking of cholinesterase by the pesticides. However it is not clear from research whether 
oximes are beneficial to patients. Hence oximes are not used for treatment in our hospital.  
Since this condition is a serious one, there is need for better treatments. In this study we are 
trying to develop a test to assess whether individual patients may benefit from oxime 
treatment. This study aims to test the levels of enzyme protein cholinesterase and the 
pesticide level in the patient‘s blood and also after adding oxime drug to the blood sample to 
increase the activity of the enzyme. This will be done on the patient‘s blood sample in the lab. 
If we can show that oximes increase the enzyme activity, then there may be a role for oxime 
treatment in such patients. Hence this test may help future patients in improving their 
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management, by deciding whether oxime therapy would be useful or not and also in 
following up these patients. 
 Participating in this study is purely voluntary and you can decide to 
withdraw your relative from the study at any time. Your relative will receive all standard 
treatment according to hospital protocols and your doctor will decide on the optimum 
treatment for your relative. This is a purely observational study and does not involve any 
additional drug treatment apart from the standard treatment. This study will not in any way 
influence the treatment that your relative is receiving in the hospital. All the patient‘s health 
records and any other data arising from the study would be kept confidential and used only 
for scientific purposes. 
Inclusion into this study involves signing a consent form and the following: 
1. Collection of clinical data including details of poisoning 
2. Daily clinical examination (which is a part of routine care) 
3. Blood tests – will be performed daily 
The procedures of the study not painful and do not cause any threat to health. Please contact 
me if you have any doubts. (Dr._____________, Phone No.______________) 
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ANNEXURE 2 – INFORMED CONSENT FORM 
Informed Consent form to participate in the study  
Study Title: A STUDY TO EVALUATE THE USE OF TRIPLE 
CHOLINESTERASE TEST IN PATIENTS WITH ORGANOPHOSPHORUS 
POISONING 
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
Name of relative:    Relationship: 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions.  
(ii)  I understand that the participation of my relative in the study is voluntary and 
that I am free to withdraw this consent at any time, without giving any reason, 
without my medical care or legal rights being affected.  
(iii)  I understand that the Ethics Committee and the regulatory authorities will not 
need my permission to look at my relative‘s health records both in respect of 
the current study and any further research that may be conducted in relation to 
it, even if I withdraw consent from the trial. I agree to this access. However, I 
understand that my relative‘s identity will not be revealed in any information 
released to third parties or published. 
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(iv)  I agree not to restrict the use of my relative‘s data or results that arise from this 
study provided such a use is only for scientific purpose(s). 
(v)  I agree to allow my relative to take part in the above study. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Date: _____/_____/______ 
Signatory‘s Name: _________________________________         Signature:  
Representative (Next of kin): _________________ 
Date: _____/_____/______ 
Signatory‘s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator‘s Name: ________________________ 
Signature or thumb impression of the Witness: ___________________________ 
Date: ____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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ANNEXURE 3 – PATIENT PROFORMA 
Clinical research form          Serial number 
Ascertainment criteria for OP poisoning (Tick appropriately): 
1. Patients who present with history of pesticide poisoning with an identified OP 
compound. 
2. Patients who present with history of pesticide poisoning with typical toxidrome of 
organophosphate poisoning, and low BChE levels. 
3. Patients who present without a history of pesticide poisoning but with typical 
toxidrome of OP poisoning and low BChE levels. 
Informed consent obtained: Yes/No 
DEMOGRAPHIC DETAILS                          
1.  Name: 
2. Hospital  ID: 
3. Age: 
4. Sex:          1.Male / 2.Female 
5. Marital status:         1.married / 2. Single / 3. Others 
6. Education:        1.Uneducated / 2.Educated   
7. Profession: 1.Unskilled/2.Semi-skilled/3.Skilled 
 
COMPOUND 
1. Compound identified:  Yes / no  
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2. Compound  name:  
3. Method by which compound identified: Name given by patient/leaflet/bottle 
brought 
4. Type of compound: 1. Dimethyl  /  2. Diethyl  / 3. Others 
5. Percentage of compound : 
6. Compound quantity(volume):  
 
DETAILS  REGARDING INGESTION 
1) Time and date of consumption:                                     
2) Time and date of First medical contact: 
3) Time and date of arrival ay CMC: 
4) Treatment given outside  :  1. Skin decontamination  /  2.Induced Emesis  /  3.  
Gastric Lavage/ 4. Atropine (dose)  /  5. PAM (dose)   / 6.Intubation 
5) Toxidrome:  1. Salivation / 2. Lacrimation / 3. Urination / 4. Defecation / 5. 
Vomiting / 6.Seizures / 7. Breathlessness / 8. Fasciculations / 9.Altered sensorium 
6) Severity of poisoning by Namba scale:  Mild/Moderate/Severe 
 
CLINICAL FEATURE – ON ADMISSION IN E&D 
1. GCS at presentation: 
2. Pupils size:            PINPOINT / DILATED/ NORMAL (2-5MM) 
3. Pulse rate at presentation: 
4. Blood pressure at presentation: 
5. Respiratory rate at presentation: 
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6. Saturation at presentation: 
7. GRBS 
8. Symptoms at presentation: 
Vomiting/diarrhoea/abdominal pain/salivation/sweating/ urinary incontinence 
/drowsiness/breathing difficulty/seizures/bleeding/giddiness/altered 
sensorium/agitation/blurring of vision/ sedation/asymptomatic 
9. Signs at presentation 
Diaphoresis 
Pupil size  
Lung crepitation 
Salivation 
Frothing at mouth 
Fasciculations/muscle weakness 
Single breath count 
Paradoxical breathing 
Abdominal tenderness 
Fever 
Severity of poisoning (by Namba Scale): Mild/Moderate/Severe 
10.Investigation:  Laboratory BChE: 
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12.Serial clinical assessment 
 DAY1 2 3 4 5 6 7 
Heart rate        
Blood 
pressure 
       
GCS        
MUSCLE 
POWER-
Shoulder  
Elbow 
Hand grip 
       
Hip        
Neck Muscle 
weakness-
neck holding 
time 
Respiratory 
muscle 
weakness 
Tidal volume 
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Pressure 
support 
PEEP 
Single breath 
count 
Miosis        
Crepitation        
Salivation        
Diarrhoea        
Cholinergic 
crises 
present/absent 
       
Atropine 
bolus dose 
given (mg) 
       
Atropine 
infusion rate 
(ml/hour * 
hours) 
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Total atropine 
dose (mg) 
       
Sedation 
present/absent 
       
 
Intermediate syndrome: Present/absent 
Duration of intermediate syndrome: 
13. Did the patient Required ICU admission 
14.Date of admission                                               date of discharge 
15.Did the patient require  ventilator support? 
16.Date intubated                                     Time intubated 
17.Indication for mechanical ventilation 
18.Duration of mechanical ventilation 
 19.Did the patient require  tracheostomy   yes no 
20.Duration of ICU stay. 
21.Complications 
 Cardiac arrest-yes/no 
 Respiratory arrest-yes/ no 
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 Infective complications-yes/ no 
o  What infection: 
o Criteria for diagnosis of infection: 
o Chest x-ray 
o Cultures: 
 Atropine delirium: Yes/No 
o Duration: 
22. Treatment: 
Gastric lavage at CMC: Yes/No 
Charcoal at CMC: Yes/No 
Atropine: Yes/No  Duration (in days): 
Total dose of atropine: 
23.Death – yes/ no 
24. Cause of death: 
Cholinergic crises 
Ventilatory and airway problems: 
Infections: 
Others: 
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Summary data: 
OP compound: -------------------------/ Unknown Concentration:   Volume: 
Severity of poisoning: Mild/Moderate/Severe 
Cholinergic crises present/absent Duration of cholinergic crises: 
Atropine duration:  Total atropine dose:  
GCS at admission: 
Duration of low GCS: 
Requirement of mechanical ventilation: Yes/No 
Duration of mechanical ventilation: 
Intermediate syndrome: Yes/No 
Duration of intermediate syndrome: 
Duration of hospitalisation 
Final outcome: Alive/ Dead/ Discharged against medical advise 
Laboratory measurements: 
11.Serial monitoring of cholinesterase 
 
 Day1 Day2 Day3  Day4 Day 5 
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0 12 24 
   
BChE( IU/L) 
 
       
RBC AChE(U/gmHB) 
 
       
Enzyme reactivability 
(U/gmHB) 
 
       
Inhibitor activity of 
patient‘s 
plasma(%inhibition) 
 
       
 
 
Name of person who filled the form and signature 
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ANNEXURE 4 – DATA AND SAMPLE COLLECTION PROTOCOL 
 
 
 
 
 
All patients of Organophosphorus poisoning presenting to CMC, 
Vellore within 30 hours of consumption 
Recruitment of patients 
Data collection 
• Type and quantity of organophosphorus compound 
• Clinical symptoms and severity 
• Treatment received elsewhere including oximes, atropine and lavage 
Point-of-care collection of samples for measurement of Plasma BChE, RBC-AChE, 
Enzyme reactivation potential with obidoxime ex-vivo, Enzyme inhibitor activity 
of patient's plasma (collected on patient arrival to CMC and no later than 30 
hours after poison consumption) 
- Serial collection of samples after 12 hours, 24 hours and every 24 hours at 12 
noon thereafter till 5 days after consumption or discharge from hospital 
- Serial assesment of clinical signs and symptoms  
- Outcome - Mechanical ventilation, Intermediate syndrome, Atropine dose 
required, duration of hospitalisation and death 
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ANNEXURE 5 – STANDARD OPERATING PROTOCOL OF TRIPLE 
CHOLINESTERASE TEST 
MATERIALS REQUIRED FOR THE ASSAYS 
1) Phosphate buffer (= PP, 0.1 M, pH 7.4) 
Solution 1: Na2HPO4*2H20, MW 177.9 (17.8 g in 1000 ml distilled water) 
Solution 2: KH2PO4, MW: 136.1 (13.6 g in 1000 ml distilled water) 
800 ml of solution 1 was mixed and adjusted with solution 2 to pH 7.4 with pH-meter and 
filtrate and stored in amber bottle at +4°C. 
2) Diluting reagent for blood dilution: Distilled water 
3) 5,5´-dithio-bis(2-nitrobenzoic acid) (= DTNB, Ellman´s reagent) 
396.3 mg DTNB (MW 396.3, Sigma) was dissolved in 100 ml of phosphate buffer (0.1 M, 
pH 7.4) and stored aliquots at ≤-20°C. The concentration is 10 mM in the solution and 0.3 
mM in the cuvet. 
4) Acetylthiocholine iodide (=ASCh) 
41.12 mg ASCh (MW 289.2, Sigma) was dissolved in 5.0 ml distilled water and stored 
aliquots at ≤-20°C. The concentration is 28.4 mM in the solution and 0.45 mM in the cuvet. 
5) S-Butyrylthiocholine iodide (= BuSCh) 
200.47 mg BuSCh (MG: 317.2, Sigma) was dissolved in 10.0 ml distilled water and stored in 
aliquots at ≤-20°C. The concentration is 63.2 mM in the solution and 1.0 mM in the cuvet.  
6) Ethopropazine (selective BChE inhibitor) 
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20.94 mg ethopropazine hydrochloride (MW 348.94, Aldrich) was dissolved in 10 ml of 0.01 
M HCl under stirring and mild heating and stored in aliquots at ≤-20°C. The concentration is 
6.0 mM in the solution and 0.02 mM in the cuvet. 
7) Transformation solution 
200 mg K3[Fe(CN)6] (MW 329.2), 50 mg KCN (MW 65,1), and 1000 mg NaHCO3 (MW 
84.0) were mixed with 1000 ml distilled water, followed by 0.5 ml Triton X-100 and stored in 
a tightly sealed amber glass bottle at ambient temperature. 
8) Obidoxime solution: 
7.54mg of obidoxime dichloride monohydrate(MW 377.2) was dissolved in 1.0ml of distilled 
water and frozen in small aliquots (50 μl) at -20C at a concentration of 20mM. 
9) Diluting reagent for test erythrocytes 
100 μl Triton X-100 (Sigma) was added to 100 ml phosphate buffer (0.1 M, pH 7.4) and 
mixed thoroughly with final concentration of Triton X-100 at 0.1% 
10) Test erythrocytes and test plasma 
Blood was taken in EDTA tube, centrifuged (10 min, 3000 rpm) and transfer plasma into tube 
(―test plasma‖). The dilute packed erythrocytes with PP were mixed, centrifuged and 
supernatant was removed. This was repeated three more times. Washed, packed erythrocytes 
were diluted with 10 volumes diluting reagent for test erythrocytes and mixed. Aliquots of 
test erythrocytes and test plasma were transferred in separate tubes and stored at ≤-20°C. 
11) Cuvets: Polystyrene cuvets (10 x 10 x 45 mm, e.g. VWR 634-0675) 
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MEASUREMENTS IN THE ASSAYS 
a) Haemoglobin content 
Sample preparation: 0.3 ml of the blood dilution and 2.7 ml of the transformation 
solution were mixed in a cuvet and extinction was read after 10 min against a 
reference cuvet containing only transformation solution. 
Conditions: Wavelength: 546 nm, Temperature: Ambient,  Extinction coefficient: 
10.8 * 10
3
M
-1
cm
-1
, Cuvets with 1 cm light path 
Calculation:  
μM Hb* = -  extinction (mA) 
          --------------------- 
   10.8 
* molarity refers to iron 
 
b) Erythrocyte AChE activity 
Conditions: Wavelength: 436 nm, Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path 
Substrate blank%:  
- 3000 μl phosphate buffer (PP), 100 μl DTNB, 10 μl ethopropazine, 50 μl ASCh 
- PP, DTNB and ethopropazine were added to cuvet, equilibrated for 10 min,  
ASCh was added and mixed 
125 
 
Sample:  
- 2800 μl PP, 100 μl DTNB, 200 μl blood dilution (sample), 10 μl ethopropazine, 
50 μl ASCh 
- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 
min, ASCh was added and mixed 
Calculation: 
            mA/min (sample) - mE/min (blank) 
μM/min =  ----------------------------------------------- 
                                11.28 
 
Referred to haemoglobin content: 
 
                        AChE activity (μM/min) * 2$ 
μM/min/μmol Hb = -------------------------------------- 
                                  μM Hb 
 
 
$ Factor for correction of different dilution in the determination of haemoglobin and 
AChE  since the whole blood specimen has been diluted with 0.1ml of sample to 
2.0ml with diluting reagent 
 
c) Reactivability 
Sample preparation: 
5 μl of Obidoxime solution(20mM) was added to 1.0ml of phosphate buffer or 1.0ml 
of patient blood dilution, incubated for 30min at 37°C 
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Conditions: Wavelength: 436 nm, Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path 
Substrate blank%:  
- 2500 μl phosphate buffer (PP), 100 μl DTNB, 10 μl ethopropazine, 500 μl 
incubate, 50 μl ASCh 
- PP, DTNB and ethopropazine were added and incubated in cuvet, equilibrated 
for 10 min, ASCh was added and mixed 
Sample:  
- 2500 μl PP, 100 μl DTNB, 500 μl incubate, 10 μl ethopropazine, 50 μl ASCh 
- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 
min, ASCh was added and mixed 
Calculation: 
             mA/min (sample) - mE/min (blank) 
μM/min =  ------------------------------------------------ 
                                11.28 
 
Referred to haemoglobin content: 
 
                           AChE activity (μM/min) * 2$ 
μM/min /μmol Hb =   ----------------------------------------- 
                             μM Hb 
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$ Factor for correction of different dilution in the determination of haemoglobin and 
AChE  since the whole blood specimen has been diluted with 0.1ml of sample to 
2.0ml with diluting reagent 
 
d) Plasma-BChE activity: 
Sample preparation: 
Thawed plasma was centrifuged with high speed for 1-2 min to remove 
cryoprecipitate. 
Conditions: Wavelength: 436 nm,  Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path 
Substrate blank%:  
- 3000 μl phosphate buffer (PP), 100 μl DTNB, 50 μl BuSCh 
- PP, DTNB and ethopropazine were added to cuvet, equilibrated for 10 
min(37°C) and reaction with BuSCh was started 
Sample:  
- 3000 μl PP, 100 μl DTNB, 10 μl sample(Plasma), 50 μl BuSCh 
- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 
min(37°C) reaction with BuSCh was started 
Calculation: 
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             mE/min (sample) - mE/min (blank) 
μM/min =  ------------------------------------------------ 
                              11.28 
 
Referred to plasma content: 
 
mU/ml plasma= μM/min * dilution factor (=316) 
 
e) Inhibitory activity 
Sample preparation: 
Thawed plasma was centrifuged with high-speed for 1-2min to remove 
cryoprecipitate. 30 μl of patient plasma was added to 100 μl test erythrocytes and 
incubated for 60 min at 37°C. Additional control was prepared by adding 30 μl test 
plasma to 100 μl test erythrocytes and incubating for 60 min at 37°C. 
Conditions: Wavelength: 436 nm, Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path 
Substrate blank%:  
- 3000 μl phosphate buffer (PP), 100 μl DTNB, 10 μl ethopropazine, 50 μl ASCh 
- PP, DTNB and ethopropazine were added to and incubated in cuvet, 
equilibrated for 10 min(37°C) and mixed with ASCh 
Sample:  
- 3000 μl PP, 100 μl DTNB, 10 μl ethopropazine, 50 μl incubate, 50 μl ASCh 
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- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 
min(37°C) and mixed with ASCh 
Calculation: 
              mE/min (sample) - mE/min (blank) 
μM/min   =  -------------------------------------------------- 
                                11.28 
 
Calculation of inhibitory activity: 
 
                      Activity incubate (Patient plasma)  
% Inhibition    =     ---------------------------------------------   * 100 
                         Activity control (Test plasma) 
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ANNEXURE 6 – DATA ABSTRACTION FORM 
CHANGING EPIDEMIOLOGY OF ADULT POISONINGS IN A TERTIARY 
CARE HOSPITAL WITH EMPHASIS ON PESTICIDE, PLANT POISONINGS 
AND DRUGS USING THE CMC POISON DATABASE 
Instruction: The Poison Control Centre database will be reviewed and the data 
abstraction form will be filled. 
1) Name: 
2) Hospital number: 
3) Age: 
4) Sex: 
5) Residence (by district): Vellore / Thiruvannamalai / Krishnagiri / Chittoor / 
Kadapa / Others 
6) Occupation: Farmer / Student / Labourer / Coolie / Housewife / Business / 
Teacher / Others 
7) Mode of poisoning: Accidental / Deliberate self-harm / Homicide / Not known 
8) Date of consumption: 
a. Month 
b. Year 
9) Name of the compound: 
10) Class of the compound: 
a. Pesticide 
i. Based on toxicity: Class Ia / Ib / II / III / Obsolete / Unlikely to 
be harmful / Unknown 
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ii. Based on category: Organophosphates / Organochlorine / 
Carbamate/ Pyrethroid / OP + Pyrethroid / Other 
b. Plant:  Oleander / Oduvanthalai / Others 
c. Drug: Drug class 
d. Corrosive: Phenol/Lysol / HCl / H2SO4 / Super vasmol / Others 
e. Rodenticide:  Zinc phosphide / Aluminium phosphide / Coumarins / 
Yellow phosphorus 
f. Unknown 
g. Mixed 
h. Others 
11) Status of admission: Ward admission / ICU admission / Casualty admission only 
12) Discharge status: Dead / Alive  / Discharge against medical advice 
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DATA SHEET 
  
 
idno case age sex preg marital edu prof compid compmthd compnamecomppct comptype compquan
1 1 20 2 1 1 2 1 1 3 dichlorvos 76 1 20
2 1 34 2 1 1 1 1 1 3 phorate 10 2 10
3 2 26 1 2 2 2 0
4 1 34 1 2 2 2 1 3 quinalphos 25 2 60
5 1 24 2 1 1 1 1 1 2 methylparathion 2 1 100
6 1 20 2 2 1 2 1 1 3 profenofos 40 3 20
7 1 26 1 1 2 1 1 3 profenofos 40 3 50
8 1 15 2 1 2 2 1 1 3 monocrotophos 36 1 20
9 1 27 1 1 2 2 1 3 dimethoate 35 1 50
10 1 27 1 2 2 2 1 3 monocrotophos 36 1 20
11 1 17 2 1 2 1 1 1 3 monocrotophos 36 1 20
12 1 24 2 1 1 1 1 1 3 dimethoate 35 1 75
13 1 19 2 1 2 2 3 1 3 quinalphos 25 2 200
14 1 25 2 1 2 1 1 1 2 profenofos 50 3 100
15 1 17 2 1 2 1 1 1 3 profenofos 40 3 250
16 1 19 1 1 1 1 1 2 dimethoate 30 1 100
17 1 20 2 1 2 1 1 1 3 monocrotophos 36 1 50
18 1 19 1 2 1 1 1 3 dimethoate 30 1 75
19 2 46 1 1 1 1 0
20 1 55 1 1 1 1 1 2 triazophos 35 2 25
21 1 45 1 1 1 1 1 3 chlorpyrifos 40 2 15
22 1 17 2 1 1 2 1 1 3 chlorpyrifos 20 2 150
23 1 45 2 1 1 1 1 1 3 triazophos 40 2 100
24 1 23 1 2 2 1 1 3 phorate 10 2 50
25 2 22 1 2 2 1 0
26 1 28 1 1 1 1 1 3 monocrotophos 30 1 10
27 2 64 2 1 1 1 1 0
28 1 24 2 1 2 1 1 3 triazophos 40 2 50
29 1 33 2 1 1 2 1 1 3 malathion 5 1 100
30 1 37 1 1 1 2 1 3 triazophos 35 2 250
comppyre pyrename doc toc toc1 fmcd fmct fmct1 cmcd cmct cmct1 timeint1 timeint2
0 14/05/2015 20 0 14/05/2015 21 15 14/05/2015 21 15 1 1
0 16/05/2015 21 0 16/05/2015 21 45 17/05/2015 9 40 1 13
20/05/2015 5 0 20/05/2015 7 30 20/05/2015 8 40 2.5 3.6
0 22/05/2015 19 45 22/05/2015 20 40 22/05/2015 20 40 1 1
0 22/05/2015 18 30 22/05/2015 21 15 22/05/2015 21 15 3 3
1 cypermethrin28/05/2015 20 0 28/05/2015 21 50 28/05/2015 21 50 2 2
1 cypermethrin28/05/2015 20 0 28/05/2015 21 50 28/05/2015 21 50 2 2
0 31/05/2015 16 0 31/05/2015 21 0 31/05/2015 22 15 5 6.2
0 04/06/2015 19 0 04/06/2015 23 50 04/06/2015 23 50 5 5
0 10/06/2015 8 30 10/06/2015 9 0 10/06/2015 21 45 0.5 13.2
0 11/06/2015 7 0 11/06/2015 8 0 11/06/2015 12 20 1 5.3
0 12/06/2015 17 0 12/06/2015 18 0 12/06/2015 20 50 1 4
0 12/06/2015 11 0 12/06/2015 12 0 12/06/2015 21 30 1 10.5
0 13/06/2015 20 0 14/06/2015 6 35 14/06/2015 6 35 10.5 10.5
1 cypermethrin14/06/2015 7 0 14/06/2015 8 0 14/06/2015 18 40 1 11.6
0 14/06/2015 11 30 14/06/2015 12 0 14/06/2015 18 20 0.5 7
0 14/06/2015 19 30 14/06/2015 20 30 15/06/2015 11 0 1 15.5
0 25/06/2015 10 0 25/06/2015 16 0 26/06/2015 15 0 4 29
28/06/2015 19 0 28/06/2015 23 0 29/06/2015 12 10 4 5
1 deltamethrin30/06/2015 14 0 30/06/2015 15 0 30/06/2015 15 30 1 1.5
1 cypermethrin07/07/2015 21 0 07/07/2015 21 30 07/07/2015 23 50 0.5 3
0 08/07/2015 11 0 08/07/2015 11 20 08/07/2015 16 40 0.4 5.7
0 10/07/2015 10 0 10/07/2015 11 0 10/07/2015 22 0 1 12
0 25/07/2015 18 30 25/07/2015 19 30 25/07/2015 23 0 1 4.5
26/07/2015 20 0 26/07/2015 22 0 26/07/2015 22 0 2 2
0 29/07/2015 14 30 29/07/2015 17 30 29/07/2015 17 30 3 3
03/08/2015 12 0 03/08/2015 13 30 03/08/2015 14 45 1.5 2.7
0 12/08/2015 9 0 12/08/2015 10 30 12/08/2015 13 30 1.5 4.5
0 14/08/2015 8 0 14/08/2015 9 20 14/08/2015 9 20 1.3 1.3
1 deltamethrin13/08/2015 15 30 13/08/2015 17 0 14/08/2015 1 0 1.5 9.5
tout toutskin toutemes toutglav toutatr atrdose toutpam pamdose toutint toxisal toxilac toxiurin toxidef toxivom
0 1 0 0 0 1
1 0 1 1 1 99 1 99 0 0 0 0 1
1 0 0 0 0 0 1 0 1 1 1
0 1 0 0 0 0
0 1 0 0 0 1
0 1 0 0 0 1
0 1 0 0 0 1
1 0 0 0 1 99 0 1 1 0 1 0 1
0 1 0 0 0 1
1 0 0 1 1 0 1 1 0 1 0 0
1 0 1 1 1 99 0 1 1 0 0 0 1
1 0 1 1 1 4 0 0 1 1 0 0 1
1 0 1 1 1 8 1 99 0 1 0 1 0 1
0 1 0 0 0 1
1 0 0 1 1 99 1 99 0 1 1 1 0 1
1 0 0 1 1 12 0 0 1 1 0 0 1
1 0 1 1 1 99 0 1 1 1 1 0 1
1 0 0 1 0 0 0 1 0 0 0 1
1 0 0 1 1 2 1 0.5 0 1 0 0 0 1
1 0 0 1 0 0 0 1 0 0 0 1
1 0 0 1 1 99 0 0 1 0 0 0 0
1 0 0 1 1 20 0 0 0 0 0 0 1
1 0 0 1 1 99 0 0 1 0 0 1 1
1 0 0 1 1 99 1 99 0 1 1 0 0 1
0 1 0 0 0 1
0 1 0 0 0 1
1 0 0 1 1 15 0 0 0 0 1 0 1
1 0 0 1 1 99 1 2 0 1 1 1 1 1
0 1 0 0 0 1
1 0 0 1 1 99 0 0 1 0 1 0 1
toxisz toxibrea toxifasc toxialts admgcs admpup admpr admbp admbp1 admrr admsat admgrbs presvom presdiar
0 0 0 0 015 3 102 120 80 20 100 204 1 0
0 1 1 0 15 3 99 120 80 34 100 222 1 0
0 0 0 0 15 1 100 170 90 20 100 139 1 1
0 1 0 1 3 1 109 100 60 99 80 150 0 0
0 0 0 0 15 3 60 110 60 20 90 162 1 0
0 0 0 0 15 3 84 120 80 24 97 130 1 0
0 0 0 0 15 1 86 120 70 24 99 130 1 0
1 1 0 0 7T 1 100 100 60 30 100 269 1 0
0 0 0 0 15 3 80 94 60 24 97 170 1 0
1 0 0 0 10T 1 86 100 60 98 96 143 1 0
0 0 0 1 3T 3 102 110 80 98 100 284 1 0
0 1 0 1 7 1 125 100 60 8 80 151 1 0
0 0 0 0 15 3 106 100 70 20 97 138 1 0
0 1 1 0 15 3 112 100 60 20 97 158 1 0
0 1 0 0 15 2 140 100 70 26 98 348 1 0
0 0 0 1 14 2 126 120 80 16 97 175 1 0
1 0 1 1 5T 1 84 100 60 98 99 200 0 0
0 0 1 0 3 1 152 90 60 99 70 193 1 0
0 0 0 0 15 3 108 120 80 20 99 148 1 0
0 0 0 0 15 1 130 120 80 22 86 177 1 0
0 0 0 0 15 3 110 110 80 20 96 95 1 0
0 0 0 0 13 2 78 110 80 21 96 98 1 0
0 0 0 1 12 1 110 110 60 24 90 216 1 0
0 0 0 0 15 3 104 110 70 24 98 92 1 0
0 1 1 1 3 3 84 140 90 99 64 192 1 0
0 0 0 0 15 3 110 120 80 20 96 170 0 0
0 0 0 0 14 3 102 90 60 22 96 159 1 0
0 0 0 1 14 3 100 100 70 26 98 229 1 0
0 0 0 0 15 3 75 100 70 24 95 94 1 0
0 1 0 1 15 1 112 100 60 44 90 194 0 0
presabpain pressal pressweat presuri presdrow presbrea pressz presbleed presgiddi presalts presagit presasym signdiap signpup
1 1 1 0 0 0 0 0 0 0 0 0 1 3
0 0 0 0 0 1 0 0 0 0 0 0 0 2
0 1 1 1 0 0 0 0 0 0 0 0 1 1
0 1 0 0 0 1 0 0 0 1 0 0 0 1
0 1 0 0 0 0 0 0 0 0 0 0 0 3
0 0 0 0 0 0 0 0 0 0 0 0 0 3
0 1 0 0 0 0 0 0 0 0 0 0 0 1
0 1 0 1 1 1 1 0 0 1 0 0 0 1
0 1 0 0 0 0 0 0 0 0 0 0 0 3
0 1 1 1 0 0 1 0 0 0 0 0 0 1
0 1 0 0 1 0 0 0 0 1 0 0 0 3
0 1 1 0 0 1 0 0 0 1 1 0 1 1
0 1 0 0 0 0 0 0 0 0 0 0 0 3
0 1 0 0 0 0 0 0 0 0 1 0 0 2
0 1 1 0 1 1 0 0 0 0 1 0 1 7
0 1 1 0 0 0 0 0 0 1 1 0 1 6
0 0 0 0 1 1 1 0 0 1 0 0 0 1
0 1 0 0 0 1 0 0 0 1 0 0 0 1
0 1 1 0 0 0 1 0 0 0 0 0 1 4
0 1 1 0 0 0 0 0 0 0 0 0 1 1
0 0 0 0 1 0 0 0 0 0 0 0 0 3
0 0 0 0 0 0 0 0 0 0 1 0 0 6
0 1 1 0 0 0 0 0 0 1 0 0 1 1
0 1 0 0 0 0 0 0 0 0 0 0 0 5
0 1 0 0 1 1 0 0 0 1 0 0 0 3
0 1 0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 1 1 0 0 0 0 0 0 0 0 2
0 1 0 1 1 0 0 0 0 0 0 0 0 5
0 1 0 0 0 0 0 0 0 0 0 0 1 4
0 1 0 0 0 1 0 0 0 0 0 0 0 1
signcrept signsal signfroth signfasc signsbc signpb signabd signfever severity hr1 bp1 bp2 gcs1 gcs2
0 1 0 0 41 0 0 0 2 102 120 80 15
0 0 0 1 21 0 0 1 3 99 120 80 15
1 1 1 0 0 0 0 0 3 110 130 70 10 T
1 1 0 0 0 1 0 0 4 106 100 60 5 T
0 1 0 0 5 0 0 0 3 60 110 60 15
0 0 0 0 99 0 0 0 2 84 120 80 15
0 1 0 0 24 0 0 0 2 86 120 70 15
1 1 0 0 99 0 0 0 4 100 120 70 7 T
0 0 0 0 0 0 0 0 2 80 94 60 15
0 0 0 1 99 0 0 0 4 86 100 60 10 T
0 1 0 0 99 0 0 0 4 102 110 80 3 T
1 1 0 0 0 0 0 0 4 125 100 60 7
0 1 0 0 24 0 0 0 2 106 100 70 15
1 1 0 1 17 0 0 0 4 112 100 60 15
1 1 1 0 0 0 0 0 4 140 100 70 15
0 1 0 0 15 0 0 0 3 126 100 60 14
0 0 0 1 99 0 0 0 4 84 100 60 5 T
1 1 0 1 99 1 0 0 4 152 90 60 3
1 1 1 0 0 0 0 0 4 108 120 80 15
0 1 0 0 20 0 0 0 2 130 120 80 15
0 0 0 0 0 0 0 0 2 100 110 80 15
0 0 0 0 30 0 0 0 2 122 100 70 13
0 1 0 0 99 0 0 0 3 102 110 60 12
0 1 0 0 30 0 0 0 2 104 110 70 15
1 1 1 1 99 1 0 0 4 84 140 90 3
0 1 0 0 16 0 0 0 2 110 120 80 15
0 0 0 1 14 0 0 0 3 102 90 60 14
1 1 0 0 13 0 0 0 3 100 100 70 14
0 1 0 0 20 0 0 0 2 75 100 70 15
1 1 0 1 0 0 0 0 4 110 100 60 15
should1 elbow1 hand1 hip1 nhf1 respweak1 ventmode1tidal1 ps1 peep1 sbc1 miosis1 crepts1 sal1
5 5 1 5 50 0 1 41 0 0 1
5 5 1 5 0 0 1 21 1 0 0
4+ 4+ 1 4+ 4 1 3 450 12 6 0 1 1 1
3 3 2 3 0 1 3 550 15 6 99 1 1 1
4 4 1 4 2 0 1 5 0 0 0
5 5 1 5 99 0 1 99 0 0 0
5 5 1 5 40 0 1 24 0 0 0
2 2 2 2 0 1 3 320 15 5 0 1 1 1
5 5 1 5 40 0 1 20 0 0 0
4 4 1 4 3 1 3 400 15 5 99 1 0 0
2 2 2 2 99 1 3 350 15 7 99 0 0 0
3 3 1 3 5 1 3 300 15 10 99 1 1 1
5 5 1 5 60 0 1 24 0 0 0
3 3 2 3 10 1 3 300 15 6 17 0 1 1
4 4 1 4 2 1 3 300 15 5 0 0 1 1
5 5 1 5 16 0 1 15 0 0 1
2 2 2 2 99 1 3 360 15 7 99 1 0 0
1 1 2 1 0 1 3 400 13 5 0 1 1 1
4 4 1 4 0 1 3 400 15 5 0 0 1 1
5 5 1 5 25 0 1 20 1 0 0
5 5 1 5 15 0 1 20 0 0 0
5 5 1 5 20 0 1 30 0 0 0
4+ 4+ 1 4+ 5 0 1 99 1 0 1
5 5 1 5 40 0 1 30 0 0 0
1 1 2 1 99 1 3 400 15 8 99 0 1 1
5 5 1 5 20 0 1 16 0 0 1
5 5 1 5 99 0 1 14 0 0 0
5 5 1 5 99 0 1 13 0 1 1
5 5 1 5 45 0 1 20 0 0 1
3 3 1 3 1 1 3 400 15 5 0 1 1 1
diarr1 cholcris1 atrbolus1 atrinf1 atrtotal1 sed1 hr2 bp3 bp4 gcs3 gcs4 should2 elbow2 hand2
0 1 0 0 0 0 90 120 80 15 5 5 1
0 1 4.8 111 115.8 0 100 130 90 15 4+ 4+ 1
0 1 39 24 63 0 90 120 60 15 5 5 1
0 1 3.6 31 34.6 1 90 130 80 2 T 1 1 2
0 1 2.4 20 22.4 0 100 110 60 2 T 1 1 2
0 1 0 0 0 0 98 90 60 15 5 5 1
0 1 1.8 18 19.8 0 80 120 60 15 5 5 1
0 1 17.2 73.5 90.7 1 140 130 90 9 T 2 2 2
0 1 1.8 0 1.8 0 140 110 70 15 5 5 1
0 1 24.4 114 138.5 1 101 130 80 7 T 4 4 1
0 1 5 23 28 1 97 110 60 7 T 3 3 1
0 1 6 24.3 30.3 1 108 100 50 10 T 3 3 1
0 1 4.8 0 4.8 0 100 100 70 15 5 5 1
0 1 39.3 98 137.3 0 118 100 60 10 T 3 3 2
0 1 2.4 55.5 57.9 0 90 120 70 10 T 4+ 4+ 1
0 1 1.2 8.5 9.7 0 106 100 60 15 5 5 1
0 1 252 426.5 678.5 1 87 110 60 2 T 1 1 2
0 1 124 203 327 1 100 120 70 10 T 3 3 2
0 1 17.4 137 154.4 0 109 150 90 8 T 1 1 2
0 1 0.6 28 28.6 0 118 120 80 15 5 5 1
0 1 2.4 24 26.4 0 102 110 80 14 5 5 1
0 0 0 0 0 0 126 110 80 15 5 5 1
0 1 1.8 9 10.8 1 100 130 70 14 4+ 4+ 1
0 0 0 0 0 0 100 110 70 15 5 5 1
0 1 1.2 44 45.2 1 105 130 80 8 T 1 1 2
0 0 0 0 0 0 100 120 80 15 5 5 1
0 1 1.8 28.5 30.3 0
0 1 3.6 36 39.6 0 128 104 70 14 5 5 1
0 1 0.6 12 12.6 0 87 110 70 15 5 5 1
0 1 16 44 60 0 100 130 90 9 T 3 3 1
hip2 nhf2 respweak2 ventmode2tidal2 ps2 peep2 sbc2 miosis2 crepts2 sal2 diarr2 cholcris2 atrbolus2
5 50 0 1 29 0 0 0 0 0 0
4+ 0 0 1 25 0 0 0 0 1 0
5 25 0 1 27 0 0 0 0 0 0
1 99 0 3 480 15 5 99 0 0 0 0 1 0.6
1 99 1 3 300 15 7 99 0 0 0 0 1 0.6
5 20 0 1 13 0 0 0 0 0 0.6
5 60 0 1 50 0 0 0 0 0 0
2 0 1 3 320 15 6 99 0 0 0 0 1 0
5 40 0 1 21 0 0 0 0 1 2
4 0 1 3 400 15 5 99 0 0 0 0 1 0
3 0 1 3 300 15 6 99 0 0 0 0 1 0
3 0 1 3 300 15 5 99 0 0 0 0 1 0
5 60 0 1 20 0 0 1 0 1 4.2
3 4 1 3 315 15 6 99 0 0 0 0 1 0
4+ 0 1 3 300 15 6 99 0 0 0 0 1 0
5 60 0 1 36 0 0 0 0 1 0
1 99 1 3 350 15 7 99 0 0 0 0 1 0
3 0 1 3 400 13 5 99 1 0 0 0 1 0
1 0 1 3 460 13 5 99 0 0 0 0 1 0
5 30 0 1 30 0 0 0 0 1 0
5 20 0 1 15 0 0 0 0 1 0
5 20 0 1 30 0 0 0 0 0 0
4+ 10 0 1 10 0 0 0 0 1 0
5 40 0 1 28 0 0 0 0 1 1.8
1 0 1 3 400 15 5 99 0 0 0 0 1 0
5 25 0 1 25 0 0 0 0 0 0
5 40 0 1 20 0 0 0 0 1 0
5 25 0 1 20 0 1 1 0 1 0
3 0 1 3 400 15 7 99 0 0 0 0 1 0
atrinf2 atrtotal2 sed2 hr3 bp5 bp6 gcs5 gcs6 should3 elbow3 hand3 hip3 nhf3 respweak3
0 0 0 90 120 80 15 5 5 1 5 50 0
66 66 0 80 100 70 10 T 4+ 4+ 1 4+ 5 1
0 0 0 80 140 80 15 5 5 1 5 35 0
256 256.6 1 110 120 70 6 T 2 2 2 2 0 1
183 183.6 1 110 110 70 9 T 3 3 2 3 0 1
0 0.6 0 90 100 60 15 5 5 1 5 20 0
4 4 0 80 120 70 15 5 5 1 5 60 0
141 141 0 90 120 70 10 T 3 3 2 3 0 1
20.5 22.5 0 122 110 70 15 5 5 1 5 40 0
645 645 1 100 150 80 10 T 4 4 1 4 2 1
23 23 1 100 120 80 15 4+ 4+ 1 4+ 40 0
47.7 47.7 0 95 110 70 10 T 4- 4- 1 4- 1 1
37.3 41.5 0 100 100 70 15 5 5 1 5 30 0
53 53 0 100 100 60 10 T 3 3 2 3 0 1
45 45 0 105 120 70 10 T 3 3 1 3 0 1
19.5 19.5 0 80 100 60 15 5 5 1 5 60 0
389 389 1 96 130 70 2 T 1 1 2 1 99 1
171 171 0 100 130 70 10 T 3 3 2 3 1 1
126 126 1 90 140 80 9 T 2 2 2 2 0 1
71.5 71.5 0 96 120 80 15 5 5 1 5 30 0
53 53 0 118 110 80 15 5 5 1 5 20 0
2 2 0 130 110 70 14 4+ 4+ 1 4+ 10 1
40.2 40.2 0 104 120 70 15 4+ 4+ 1 4+ 10 0
0 1.8 0 105 110 70 15 5 5 1 5 40 0
110 110 1 110 120 80 8 T 3 3 2 3 5 1
0 0 0 90 120 80 15 5 5 1 5 35 0
19 19 0 94 110 70 15 5 5 1 5 40 0
2 2 0 86 110 70 15 5 5 1 5 25 0
132 132 0 96 130 90 10 T 3 3 1 3 5 1
ventmode3tidal3 ps3 peep3 sbc3 miosis3 crepts3 sal3 diarr3 cholcris3 atrbolus3 atrinf3 atrtotal3 sed3
1 40 0 0 0 0 0 0 0 0 0
2 541 10 6 99 0 0 0 0 1 0 0 0 0
1 37 0 0 0 0 0 0 0 0 0
2 423 15 5 99 0 0 0 0 1 0 85 85 1
3 300 15 5 99 0 0 0 0 1 0 19 19 1
1 20 0 0 0 0 0 0 0 0 0
1 50 0 0 0 0 0 0 0 0 0
2 292 15 6 99 0 0 0 0 1 0 59 59 0
1 20 0 0 0 0 0 0 6.5 6.5 0
3 400 15 5 99 0 0 0 0 1 0 69 69 0
1 20 0 0 0 0 0 0 0 0 0
3 300 15 5 99 0 0 0 0 1 0 36 36 0
1 20 0 0 1 0 1 0 25 25 0
3 285 15 6 99 0 0 0 0 1 0 0 0 0
3 300 15 5 99 0 0 0 0 1 0 16 16 0
1 40 0 0 0 0 0 0 24 24 0
3 350 15 7 99 0 0 0 0 1 0 545 545 1
2 450 9 5 99 0 0 0 0 1 0 74 74 0
3 450 15 6 99 0 0 0 0 0 0 3 3 0
1 30 0 0 0 0 1 0 75 75 0
1 15 0 0 0 0 1 0 48 48 0
1 6 0 0 0 0 0 0 0 0 0
1 10 0 0 0 0 1 0 75 75 0
1 30 0 0 0 0 0 2.4 0 2.4 0
3 400 15 5 99 0 0 0 0 1 0 52 52 0
1 25 0 0 0 0 0 0 0 0 0
1 20 0 0 0 0 0 0 3 3 0
1 30 0 0 0 0 0 0 0 0 0
2 500 15 7 99 0 0 0 0 1 0 44 44 0
hr4 bp7 bp8 gcs7 gcs8 should4 elbow4 hand4 hip4 nhf4 respweak4 ventmode4tidal4 ps4
86 120 80 15 5 5 1 5 50 0 1
80 80 50 10 T 4+ 4+ 1 4+ 15 1 3 500 8
80 130 80 15 5 5 1 5 40 0 1
110 120 80 7 T 3 3 2 3 0 1 2 375 10
90 130 80 15 4- 4- 1 4- 5 0 1
85 100 60 15 5 5 1 5 20 0 1
80 120 70 15 5 5 1 5 60 0 1
120 130 70 10 T 3 3 1 3 1 1 3 323 18
100 110 70 15 5 5 1 5 40 0 1
90 120 70 10 T 4 4 1 4 2 1 3 400 15
90 120 80 15 5 5 1 5 60 0 1
120 100 50 10 T 4- 4- 1 4- 4 0 3 310 15
98 100 70 15 4 4 1 4 15 0 1
126 100 60 10 T 2 2 2 2 0 1 3 470 14
105 130 80 10 T 3 3 1 3 0 1 3 300 12
80 100 60 15 5 5 1 5 60 0 1
107 130 70 2 T 1 1 2 1 99 1 3 350 15
70 140 70 10 T 4 4 1 4 10 1 2 450 10
100 140 80 9 T 2 2 2 2 0 1 3 450 15
90 120 80 15 5 5 1 5 40 0 1
94 110 80 15 5 5 1 5 30 0 1
106 100 70 15 5 5 1 5 20 0 1
102 120 70 10 T 2 2 1 2 5 1 3 360 15
106 110 70 15 5 5 1 5 40 0 1
100 120 80 10 T 5 5 1 5 20 0 2 407 15
88 100 70 14 5 5 1 5 40 0 1
85 110 70 15 5 5 1 5 40 0 1
81 140 80 10 T 5 5 1 5 20 0 2 500 10
peep4 sbc4 miosis4 crepts4 sal4 diarr4 cholcris4 atrbolus4 atrinf4 atrtotal4 sed4 hr5 bp9 bp10
40 0 0 0 0 0 0 0 0 0 85 120 80
9 99 0 0 0 0 0 0 0 0 0 85 110 70
40 0 0 0 0 0 0 0 0 0
5 99 0 0 0 0 0 0 0 0 1 80 110 70
7 0 0 0 0 0 0 0 0 0 106 110 70
20 0 0 0 0 0 0 0 0 0
50 0 0 0 0 0 0 0 0 0 80 120 80
6 99 0 0 0 0 1 0 36 36 0 120 120 70
25 0 0 0 0 0 0 0 0 0 90 110 70
5 99 0 0 0 0 0 0 1 1 0 100 120 70
25 0 0 0 0 0 0 0 0 0 84 120 80
5 99 0 0 0 0 0 0 0 0 0 100 100 60
5 0 0 0 0 0 0 1 1 0 80 100 70
9 99 0 0 0 0 0 0 0 0 0 88 100 60
5 99 0 0 0 0 0 0 0 0 0 88 100 70
50 0 0 0 0 0 0 5.5 5.5 0 58 100 60
7 99 0 0 0 0 1 0 460 460 1 100 130 70
5 99 0 0 0 0 0 0 20 20 0 85 130 90
9 99 0 0 0 0 0 0 0 0 0 100 120 80
30 0 0 0 0 1 0 29 29 0 96 120 80
40 0 0 0 0 1 0 21 21 0 98 110 80
60 0 0 0 0 0 0 0 0 0 108 100 70
5 99 0 0 0 0 0 0 84 84 0 96 120 70
30 0 0 0 0 0 1.8 0 1.8 0 96 110 70
5 99 0 0 0 0 0 0 0 0 0 90 120 80
26 0 0 0 0 0 0 0 0 0 88 100 70
30 0 0 0 0 0 0 0 0 0 80 110 70
6 99 0 0 0 0 1 0 24 24 0 80 100 70
gcs9 gcs10 should5 elbow5 hand5 hip5 nhf5 respweak5 ventmode5tidal5 ps5 peep5 sbc5 miosis5
15 5 5 1 5 50 0 1 40 0
10 T 3 3 1 3 0 1 2 300 6 7 99 0
7 T 2 2 2 2 2 1 3 450 15 8 99 0
15 4+ 4+ 1 4+ 15 0 1 10 0
15 5 5 1 5 60 0 1 50 0
10 T 3 3 1 3 1 1 3 300 15 6 99 0
15 5 5 1 5 40 0 1 25 0
10 T 5 5 1 5 40 0 2 381 15 5 99 0
15 5 5 1 5 60 0 1 30 0
10 T 4 4 1 4 15 0 2 371 15 5 99 0
15 5 5 1 5 15 0 1 10 0
10 T 4- 4- 1 4- 5 1 3 280 15 7 99 0
10 T 4- 4- 1 4- 5 1 3 306 12 5 99 0
15 5 5 1 5 60 0 1 54 0
2 T 1 1 2 1 99 1 3 400 15 7 99 0
10 T 4+ 4+ 1 4+ 30 1 2 400 10 5 99 0
9 T 2 2 2 2 0 1 3 400 15 9 99 0
15 5 5 1 5 40 0 1 30 0
15 5 5 1 5 30 0 1 40 0
15 5 5 1 5 20 0 1 60 0
10 T 4+ 4+ 1 4+ 5 1 3 360 15 5 99 0
15 5 5 1 5 40 0 1 30 0
15 5 5 1 5 45 0 1 10 0
15 5 5 1 5 40 0 1 26 0
15 5 5 1 5 40 0 1 30 0
15 5 5 1 5 20 0 1 99 0
crepts5 sal5 diarr5 cholcris5 atrbolus5 atrinf5 atrtotal5 sed5 insyn insyndur icu icudur vent ventind
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 3 1 6 1 2
0 1 2 1 3
0 0 0 0 0 0 0 1 1 5 1 9 1 1
0 0 0 0 0 0 0 0 0 1 3 1 2
0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 9 1 16 1 3
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 1 7 1 1
0 0 0 0 0 0 0 0 0 1 4 1 1
0 0 0 0 0 0 0 0 0 1 6 1 3
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 1 8 1 11 1 3
0 0 0 0 0 0 0 0 1 10 1 16 1 2
0 0 0 0 0 9.5 9.5 0 0 0 0
0 0 0 0 0 0 0 1 0 1 5 1 1
0 0 0 0 0 0 0 0 1 2 1 7 1 1
0 0 0 0 0 0 0 0 1 17 1 19 1 3
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 5 5 0 0 0 0
0 0 0 0 0 0 0 0 1 1 1 2 0
0 0 0 0 0 10.5 10.5 0 1 11 1 8 1 2
0 0 0 0 1.2 0 1.2 0 0 0 0
0 0 0 0 0 0 0 0 0 1 5 1 3
0 0 0
0 0 1 2
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 7 7 0 1 11 1 10 1 2
intday ventdur trach cardarr resparr infec infec1 infec2 atrdel inotrop lowgccs cmcglav cmcchar cmcatr
0 0 0 0 0 0 1 1 0
2 5 0 0 0 1 3 0 1 0 1 0 1
1 1.2 0 0 0 0 0 0 0 1 0 1
1 8 0 0 0 1 1 0 0 5 1 1 1
2 2 0 0 0 0 0 0 1 1 0 1
0 0 0 0 0 0 1 1 1
0 0 0 0 0 0 1 0 1
1 14 0 0 0 1 1 3 0 0 1 0 0 1
0 0 0 0 0 0 1 1 1
1 6 0 0 0 0 0 0 2 0 0 1
1 2 0 0 0 0 0 0 2 1 1 1
1 6 0 0 0 0 0 0 1 1 0 1
0 0 0 0 0 0 0 0 1
1 11 0 0 0 1 1 0 0 0 1 1 1
1 13 1 0 0 1 1 0 0 0 0 0 1
0 0 0 0 0 0 1 0 1
1 5 0 0 1 1 1 0 1 5 0 0 1
2 6 0 0 0 0 0 0 1 0 0 1
1 14 1 0 0 1 1 0 0 1 1 0 0
0 0 0 0 0 0 1 1 1
0 0 0 0 0 0 1 1 1
0 0 0 0 0 0 1 1 1
4 11 0 0 0 1 1 0 0 1 0 0 1
0 0 0 0 0 0 0 0 1
1 4 0 0 0 0 0 0 1 1 1 1
0 0 0 0 0 0 1 1 0
1 0 0 0 1 0 0 0 0 1 1 1
0 0 1 1 1 0 0 1 1 1
0 0 0 0 0 0 1 1 1
1 9 1 0 0 1 1 0 0 0 0 0 1
atrdur atrdose1 death deathcauseoutcome hospdur
0 0 0 1 5
2 181.8 0 1 9
1 63 0 1 4
3 376.2 0 1 11
3 225 0 1 7
1 0.6 0 1 5
2 23.8 0 1 5
4 326.7 0 1 19
3 30.8 0 1 5
4 853.5 0 1 8
2 51 0 1 7
3 114 0 1 8
4 72.3 0 1 6
2 190.3 1 2 2 11
3 118.9 0 1 27
6 69.2 0 1 6
4 2072.5 1 2 2 5
4 592 0 1 9
3 283.4 0 1 27
4 204.1 0 1 8
4 148.4 0 1 7
1 2 0 1 6
5 220.5 0 1 26
4 7.2 0 1 7
3 207.2 0 1 6
0 0 0 1 3
1 30.3 1 3 2 1
3 61.6 0 1 5
2 14.6 0 1 5
5 267 0 1 20
idno preoximestatpreoxime1 preoxime2 preoxime3 preoxime4 preoxime5 postoxstat postox1
1 94.77% 40.78% 26.52% 111.11% 67.12%
2 44.33% 38.37% 22.57% 28.97% 34.37% 21.76% 191.20% 178.53%
3 22.29% 43.54% 55.67% 57.51% 144.56% 101.15%
4 91.48% 150.89% 197.18% 113.49% 295.28% 213.56% 116.33% 181.85%
5 104.65% 75.04% 94.39% 107.18% 92.41% 99.58% 135.74% 112.75%
6 249.85% 193.66% 233.47% 249.91% 294.54% 245.65%
7 37.03% 16.01% 15.21% 72.14% 51.92% 37.34%
8 0.00% 9.64% 9.02% 11.00% 0.00% 19.68% 33.38% 20.29%
9 11.00% 43.76% 99.09% 108.48% 32.51% 73.68%
10 7.54% 6.68% 7.79% 19.78% 13.18% 13.83% 11.87% 0.00%
11 194.96% 223.83% 158.49% 93.15% 74.79% 91.98% 175.80% 309.50%
12 23.39% 24.91% 11.71% 24.34% 29.24% 26.01% 22.54% 14.95%
13 50.80% 50.80% 30.00% 34.78% 35.55% 21.11% 88.36% 88.36%
14 20.47% 49.48% 7.76% 20.35% 15.52% 9.76% 22.04% 50.15%
15 19.33% 17.38% 9.10% 18.77% 32.03% 17.23% 12.04% 8.43%
16 19.57% 11.96% 17.64% 22.73% 22.01% 57.80% 19.84% 12.45%
17 16.06% 7.44% 7.78% 16.08% 19.85% 20.84% 21.91%
18 8.86% 2.69% 0.00% 1.54% 2.33% 15.39% 0.00% 10.53%
19 4.37% 1.06% 1.04% 0.00% 10.71% 0.00% 6.07% 7.05%
20 28.84% 6.04% 8.16% 0.00% 25.00% 1.08% 80.06% 29.94%
21 33.78% 2.38% 0.21% 4.05% 4.75% 79.08% 7.15%
22 26.14% 15.41% 1.79% 12.11% 16.92% 43.45% 59.42%
23 16.83% 16.83% 8.28% 5.26% 0.00% 1.97% 74.26% 74.26%
24 112.25% 101.33% 131.67% 123.36% 15.72% 115.68% 153.06%
25 24.77% 18.68% 16.41% 4.12% 12.09% 88.83% 85.16%
26 90.51% 110.45% 91.86% 121.88%
27 2.28% 5.84%
28 10.49% 26.47% 2.87% 50.26% 112.94% 77.81%
29 100.14% 109.51% 106.42% 118.77% 103.90% 110.57% 130.68%
30 18.60% 13.29% 0.00% 7.60% 0.00% 6.74% 107.83% 95.18%
postox2 postox3 postox4 postox5 %reactstat %react1 %react2 %react3 %react4
57.84% 16.34% 26.34% 31.32%
102.49% 133.10% 81.08% 95.16% 146.87% 140.16% 79.92% 104.13% 46.71%
89.84% 82.77% 122.27% 57.61% 34.17% 25.26%
245.58% 135.56% 421.26% 255.41% 24.85% 30.96% 48.40% 22.07% 125.98%
111.51% 129.37% 132.90% 132.59% 31.09% 37.71% 17.12% 22.19% 40.49%
265.92% 214.00% 44.69% 51.99% 32.45% -35.91%
40.61% 86.79% 14.89% 21.33% 25.40% 14.65%
29.18% 56.23% 0.00% 21.64% 33.38% 10.65% 20.16% 45.23% 0.00%
124.92% 129.99% 21.51% 29.92% 25.83% 21.51%
9.52% 16.69% 0.00% 6.48% 4.33% -6.68% 1.73% -3.09% -13.18%
174.50% 129.75% 90.87% 125.48% -19.16% 85.67% 16.01% 36.60% 16.08%
10.15% 12.54% 0.00% 0.00% -0.85% -9.96% -1.56% -11.80% -29.24%
61.62% 49.52% 43.26% 40.58% 37.56% 37.56% 31.62% 14.74% 7.71%
20.69% 0.00% 13.18% 10.53% 1.57% 0.67% 12.93% -20.35% -2.34%
3.84% 22.77% 12.63% 24.80% -7.29% -8.95% -5.26% 4.00% -19.40%
9.02% 23.39% 19.56% 52.87% 0.27% 0.49% -8.62% 0.66% -2.45%
4.79% 3.41% 7.20% 4.78% 14.47% -2.99% -12.67% -12.65%
2.95% 0.44% 0.52% 11.76% -8.86% 7.84% 2.95% -1.10% -1.81%
4.16% 74.00% 5.35% 5.86% 1.70% 5.99% 3.12% 74.00% -5.36%
28.10% 25.11% 13.83% 11.37% 51.22% 23.90% 19.94% 25.11% -11.17%
0.42% 6.94% 8.49% 45.30% 4.77% 0.21% 2.89% 3.74%
57.95% 47.32% 27.83% 17.31% 44.01% 56.16% 35.21%
33.14% 20.23% 15.67% 7.61% 57.43% 57.43% 24.86% 14.97% 15.67%
132.08% 128.44% 32.73% 3.43% 51.73% 0.41% 5.08% 17.01%
45.68% 49.24% 31.10% 64.06% 66.48% 29.27% 45.12% 19.01%
1.35% 11.43%
3.56%
103.37% 64.18% 102.45% 51.34% 100.50% 13.92%
114.87% 113.60% 127.26% 30.54% -109.51% 8.45% -118.77% 9.70%
65.31% 62.42% 38.59% 32.77% 89.23% 81.89% 65.31% 54.82% 38.59%
%react5 react durationinh stat inh 2 inh 3 inh 4 inh 5
0
73.40% 6 41.00% 59.00% 61.00% 84.00% 90.00%
1
41.85% 0
33.01% 0 88.00% 94.00% 91.00% 97.00%
0 206.00% 97.00% 99.00% 90.00%
2 95.00% 98.00% 87.00% 86.00%
1.96% 1 93.00% 88.00% 90.00% 94.00%
1 95.00% 91.00% 74.00% 88.00%
-7.35% 0 121.00% 115.00% 112.00% 99.00% 78.00%
33.50% 0 102.00% 119.00% 107.00% 110.00%
-26.01% 0 66.00% 96.00% 78.00% 91.00% 82.00%
19.47% 2 97.00% 118.00% 105.00% 83.00%
0.77% 0 96.00% 78.00% 97.00% 65.00% 86.00%
7.57% 0 92.00% 79.00% 78.00% 81.00% 111.00%
-4.93% 0 90.00% 99.00% 79.00% 89.00% 107.00%
0.00% 0 59.00% 93.00% 79.00% 95.00%
-3.63% 0 85.00% 93.00% 90.00% 94.00% 92.00%
5.86% 0 82.00% 65.00% 64.00% 86.00% 82.00%
10.29% 1 88.00% 74.00% 94.00% 86.00% 87.00%
0.5 114.00% 115.00% 120.00% 102.00%
10.91% 3 110.00% 116.00% 112.00% 90.00%
5.64% 2 88.00% 100.00% 92.00% 88.00% 91.00%
0
4
0
0
2 89.00% 78.00% 92.00% 88.00%
16.69% 0
26.03% 5 72.00% 64.00% 79.00% 81.00% 86.00%
